

PCL Department Publications (2012)

Al-Awar R

Senisterra G, Wu H, Allali-Hassani A, Wasney GA, Barsyte-Lovejoy D, Dombrowski L, Dong A, Nguyen KT, Smil D, Bolshan Y, Hajian T, He H, Seitova A, Chau I, Li F, Poda G, Couture JF, Brown PJ, **Al-Awar R**, Schapira M, Arrowsmith CH, Vedadi M. Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5. *Biochem J.*; 449(1):151-9, 2012.

Siarheyeva A, Senisterra G, Allali-Hassani A, Dong A, Dobrovetsky E, Wasney GA, Chau I, Marcellus R, Hajian T, Liu F, Korboukh I, Smil D, Bolshan Y, Min J, Wu H, Zeng H, Loppnau P, Poda G, Griffin C, Aman A, Brown PJ, Jin J, **Al-Awar R**, Arrowsmith CH, Schapira M, Vedadi M. An allosteric inhibitor of protein arginine methyltransferase 3. *Structure.*; 20(8):1425-35, 2012.

Trzcinska-Daneluti AM, Nguyen L, Jiang C, Fladd C, Uehling D, Prakesch M, **Al-Awar R**, Rotin D. Use of kinase inhibitors to correct $\Delta F508$ -CFTR function. *Mol Cell Proteomics.*; 11(9):745-57, 2012.

Ho KS, Aman AM, **Al-Awar RS**, Shoichet MS. Amphiphilic micelles of poly(2-methyl-2-carboxytrimethylene carbonate-co-D,L-lactide)-graft-poly(ethylene glycol) for anti-cancer drug delivery to solid tumours. *Biomaterials.*; 33(7):2223-9, 2012.

McDermott SP, Eppert K, Notta F, Isaac M, Datti A, **Al-Awar R**, Wrana J, Minden MD, Dick JE. A small molecule screening strategy with validation on human leukemia stem cells uncovers the therapeutic efficacy of kinetin riboside. *Blood.*; 119(5):1200-7, 2012.

Yu W, Chory EJ, Wernimont AK, Tempel W, Scopton A, Federation A, Marineau JJ, Qi J, Barsyte-Lovejoy D, Yi J, Marcellus R, Iacob RE, Engen JR, Griffin C, Aman A, Wienholds E, Li F, Pineda J, Estiu G, Shatseva T, Hajian T, **Al-Awar R**, Dick JE, Vedadi M, Brown PJ, Arrowsmith CH, Bradner JE, Schapira M. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. *Nat Commun.*; 3:1288, 2012.

Andreazza AC

Kim HK, **Andreazza AC**. The relationship between oxidative stress and post-translational modification of the dopamine transporter in bipolar disorder. *Expert Rev Neurother.*; 12(7):849-59, 2012.

Scola G, Kim HK, Young LT, **Andreazza AC**. A fresh look at complex I in microarray data: clues to understanding disease-specific mitochondrial alterations in bipolar disorder. *Biol Psychiatry.* 15;73(2):e4-5, 2012.

Andreazza AC. Combining redox-proteomics and epigenomics to explain the involvement of oxidative stress in psychiatric disorders. *Mol Biosyst.*; 8(10):2503-12, 2012.

Tramontina AC, Nardin P, Quincozes-Santos A, Tortorelli L, Wartchow KM, **Andreazza AC**, Braganhol E, de Souza DO, Gonçalves CA. High-glucose and S100B stimulate glutamate uptake in C6 glioma cells. *Neurochem Res.*; 37(7):1399-408, 2012.

Valiengo LL, Soeiro-de-Souza MG, Marques AH, Moreno DH, Juruena MF, **Andreazza AC**, Gattaz WF, Machado-Vieira R. Plasma cortisol in first episode drug-naïve mania: differential levels in euphoric versus irritable mood. *J Affect Disord.*; 138(1-2):149-52. , 2012.

Diehl LA, Alvares LO, Noschang C, Engelke D, **Andreazza AC**, Gonçalves CA, Quillfeldt JA, Dalmaz C. Long-lasting effects of maternal separation on an animal model of post-traumatic stress disorder: effects on memory and hippocampal oxidative stress. *Neurochem Res.*; 37(4):700-7, 2012.

Boutros PC

Nichols AC, Chan-Seng-Yue M, Yoo J, Xu W, Dhaliwal S, Basmaji J, Szeto CC, Dowthwaite S, Todorovic B, Starmans MHW, Lambin P, Palma DA, Fung K, Franklin JH, Wehrli B, Kwan K, Koropatnick J, Mymryk JS, **Boutros P**, Barrett JW. A pilot study comparing HPV-positive and HPV-negative head and neck squamous cell carcinomas by whole exome sequencing ISRN *Oncology* 809370:1-9, 2012.

Lipina TV, Haque FN, McGirr A, **Boutros PC**, Berger T, Mak TW, Roder JC, Wong AH (2012) Prophylactic Valproic Acid Treatment Prevents Schizophrenia-Related Behaviour in Disc1-L100P Mutant Mice, *PLoS One* 7(12):e51562, 2012.

Starmans MHW, Pintilie M, John T, Der SD, Shepherd FA, Jurisica I, Lambin P, Tsao MS, **Boutros PC**. Exploiting the noise: improving biomarkers with ensembles of data analysis methodologies *Genome Medicine* 4(11):84, 2012.

Kim Y, Ignatchenko V, Yao CQ, Kalatskaya I, Nyalwidhe JO, Lance RS, Gramolini AO, Troyer DA, Stein LD, **Boutros PC**, Medin JA, Semmes OJ, Drake RR, Kislinger T. Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer *Molecular & Cellular Proteomics* 11(12):1870-84, 2012.

Yu M, Lin G, Arshadi N, Kalatskaya I, Xue B, Haider S, Nguyen F, **Boutros PC**, Elson A, Muthuswamy LB, Tonks NK, Muthuswamy SK. Expression profiling during mammary epithelial cell 3D morphogenesis identifies PTPRO as a novel regulator of morphogenesis and ErbB2 mediated transformation *Molecular and Cellular Biology* 32(19):3913-24, 2012.

Starmans MHW, Lieuwes NG, Span PN, Haider S, Dubois L, Nguyen F, van Laarhoven HW, Sweep FCGJ, Wouters BG, **Boutros PC**, Lambin P. Independent and Functional Validation of a Multi-Tumour-Type Proliferation Signature *British Journal of Cancer* 107(3):508-15, 2012.

Chand D, Song L, Delannoy L, Barsyte-Lovejoy D, Ackloo S, **Boutros PC**, Evans K, Belsham DD, Lovejoy DA. C-terminal region of teneurin-1 co-localizes with dystroglycan and modulates cytoskeletal organization through an ERK-dependent stathmin- and filamin A-mediated mechanism in hippocampal cells *Neuroscience* 219:255-70, 2012.

Cortese R, Kwan A, Lalonde ER, Bryzgunova O, Bondar A, Wu Y, Gordevicius J, Park M, Oh G, Kaminsky Z, Tverkuvienė J, Laurinavicius A, Jankevicius F, Sendorek DHS, Haider S, Wang S-C, Jarmalaite S, Laktionov P, **Boutros PC**, Petronis A. Epigenetic markers of prostate cancer in plasma circulating DNA *Human Molecular Genetics* 21(16):3619-31, 2012.

Lapuk AV, Wu C, Wyatt AW, McPherson A, McConeghy BJ, Brahmabhatt S, Mo F, Zoubeidi A, Anderson S, Bell RH, Haegert A, Shukin R, Wang Y, Fazli L, Hurtado-Coll A, Jones EC, Hach F, Hormozdiari F, Hajiresouliha I, **Boutros PC**, Bristow RG, Zhao Y, Marra MA, Fanjul A, Maher CA, Chinnaiyan AM, Rubin MA, Beltran H, Sahinalp SC, Gleave ME, Volik SV, Collins CC. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. *Journal of Pathology* 227(3):286-97, 2012

Waggott D, Chu K, Yin S, Wouters BG, Liu F-F, **Boutros PC**. NanoStringNorm: An Extensible R Package For the Pre-Processing of NanoString mRNA and miRNA Data, *Bioinformatics* 28(11):1546-1548, 2012.

Luong ML, Hosseini-Moghaddam SM, Singer LG, Chaparro C, Azad S, Lazar N, **Boutros PC**, Keshavjee S, Rotstein C, Husain S. Risk Factors for Voriconazole Hepatotoxicity at 12 Weeks in Lung Transplant Recipients, *American Journal of Transplantation* 12(7):1929-1935, 2012.

Starmans MHW, Chu KC, Haider S, Nguyen F, Seigneuric R, Magagnin MG, Koritzinsky M, Kasprzyk A, **Boutros PC**, Wouters BG, Lambin P. The prognostic value of temporal in vitro and in vivo derived hypoxia gene-expression signatures in breast cancer, *Radiotherapy and Oncology* 102(3):436-443, 2012.

Yao CQ, Prokopec SD, Watson JD, Pang R, P'ng C, Chong LC, Harding NJ, Pohjanvirta R, Okey AB, **Boutros PC**. Inter-Strain Heterogeneity in Rat Hepatic Transcriptomic Responses to 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), *Toxicology & Applied Pharmacology* 260(2):135-145, 2012.

Wu C, Wyatt AW, Lapuk AV, McPherson A, McConeghy BJ, Bell RH, Anderson S, Haegert A, Brahmabhatt S, Shukin R, Mo F, Li E, Fazli L, Hurtado-Coll A, Jones EC, Butterfield YS, Hach F, Hormozdiari F, Hajirasouliha I, **Boutros PC**, Bristow RG, Jones SJ, Hirst M, Marra MA, Maher CA, Chinnaiyan AM, Sahinalp SC, Gleave ME, Collins CC. Integrated genome, exome, and transcriptome analysis identifies a new and aggressive prostate cancer subtype, *Journal of Pathology* 227(1):53-61, 2012.

Ng T, Chand D, Song L, Watson JD, **Boutros PC**, Belsham D, Baryste-Lovejoy D, Lovejoy DA. Identification of a novel Brain Derived Neurotrophic Factor (BDNF)-inhibitory factor: Regulation of BDNF by Teneurin C-terminal Associated Peptide (TCAP)-1 in immortalized embryonic mouse hypothalamic cell, *Regulatory Peptides* 174(1:3):79-89, 2012.

Brands B

Rush B, Castel S, **Brands B**, Toneatto T, Veldhuizen S. Validation and comparison of diagnostic accuracy of four screening tools for mental disorders in people seeking treatment for substance use disorders. *J Subst Abuse Treat.* 2012 Oct 22. [Epub ahead of print].

Stoduto G, Mann RE, Ialomiteanu A, Wickens CM, **Brands B**. Examining the link between collision involvement and cocaine use. *Drug Alcohol Depend.* 1;123(1-3):260-3, 2012.

Burnham WM

Trépanier MO, Taha AY, Mantha RL, Ciobanu FA, Zeng QH, Tchkhartichvili GM, Domenichiello AF, Bazinet RP, **Burnham WM**. Increases in seizure latencies induced by subcutaneous docosahexaenoic acid are lost at higher doses. *Epilepsy Res.* 99(3):225-32, 2012.

Chirgadze N

Gordon RD, Qiu W, Romanov V, Lam K, Soloveychik M, Benetteraj D, Battaile KP, **Chirgadze YN**, Pai EF, Chirgadze NY. Crystal structure of the CN-hydrolase SA0302 from the pathogenic bacterium *Staphylococcus aureus* belonging to the Nit and NitFhit Branch of the nitrilase superfamily. *J Biomol Struct Dyn.* 2012 Oct 2. [Epub ahead of print].

Dorian P

Ha AH, Ham I, Nair GM, Connolly SJ, **Dorian P**, Morillo CA, Healey JS. Implantable ardioverter-defibrillator shock prevention does not reduce mortality: A systemic review. *Heart Rhythm.* 9(12):2068-74, 2012.

Lopes RD, Al-Khatib SM, Wallentin L, Yang H, Ansell J, Bahit MC, De Caterina R, **Dorian P**, Easton JD, Erol C, Ezekowitz JA, Gersh BJ, Granger CB, Hohnloser SH, Horowitz J, Hylek EM, McMurray JJ, Mohan P, Vinereanu D, Alexander JH. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. *Lancet.* 17;380(9855):1749-58, 2012.

Joshi SB, Connelly KA, Jimenez-Juan L, Hansen M, Kirpalami A, **Dorian P**, Mangat I, Al-Hesayen A, Cream AM, Wright GA, Yan AT, Leong-Poi H. Potential clinical impact of cardiovascular magnetic resonance assessment of ejection fraction on eligibility for cardioverter defibrillator implantation. *J Cardiovasc Magn Reson.* 8; 14:69, 2012.

Ha A, **Dorian P**. Health-related quality of life questionnaires: an important method to evaluate patient outcomes in atrial fibrillation ablation. *J Interv Card Electrophysiol.* 2012 Oct 10. [Epub ahead of print].

Ramadeen A, **Dorian P**. How Are n-3 LCPUFAs Antiarrhythmic? A Reassessment of n-3 LCPUFAs in Cardiac Disease. *Cardiol Res Pract.* 2012:746709, 2012.

Ramadeen A, Connelly KA, Leong-Poi H, Hu X, Fujii H, Laurent G, Domenichiello AF, Bazinet RP, **Dorian P**. Docosahexaenoic acid, but not eicosapentaenoic acid, supplementation reduces vulnerability to atrial fibrillation. *Circ Arrhythm Electrophysiol.* 5(5):978-83, 2012.

Coppens M, Eikelboom JW, Hart RG, Yusuf S, Lip GYH, **Dorian P**, Shestakovska O, Connolly SJ. The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. *Eur Heart J.* 2012 Sep 27.

Ramadeen A, Connelly KA, Leong-Poi H, Hu X, Fujii H, VanKrieden R, Laurent G, Holub BJ, Bazinet RP, **Dorian P**. n-3 polyunsaturated fatty acid supplementation does not reduce vulnerability to atrial fibrillation in remodeling atria. *Heart Rhythm*. [Epub ahead of print]; 9(7):1115-22, 2012.

Frasure-Smith N, Lespérance, Talajic M, Khairy P, **Dorian P**, O'Meara E, Roy D. Anxiety sensitivity moderates prognostic importance of rhythm- versus rate-control strategies in patients with atrial fibrillation and congestive heart failure: insights from the AF-CHF trial. *Circ Heart Fail*, 5(3):322-30, 2012.

DeVos CB, Breithardt G, Camm AJ, **Dorian P**, Kowey PR, LeHeuzey JY, Naditch-Brûlé L, Prystowsky EN, Schwartz PJ, Torp-Pedersen C, Weintraub WS, Crijns HJ. Progression of atrial fibrillation in the Registry on Cardiac rhythm disorders assessing the control of Atrial Fibrillation cohort: Clinical correlates and the effect of rhythm-control therapy. *Am Heart J*;163(5):887-93, 2012.

O'Reilly DJ, Hopkins RB, Healey JS, **Dorian P**, Sauriol L, Tarride JE, Burke N, Goeree RA. The burden of atrial fibrillation on the hospital sector in Canada. *Can J Cardiol*. 2012 May 30 [Epub ahead of print].

Skane AC, Healey JS, Cairns JA, **Dorian P**, Gillis AM, McMurtry MS, Mitchell LB, Verma A, Nattel S; Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee. Focused 2012 update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for stroke prevention and rate/rhythm control. *Can J Cardiol*. 28(2):125-36, 2012.

MacFadden DR, Crystal E, Krahn AD, Mangat I, Healey JS, **Dorian P**, Birnie D, Simpson CS, Khaykin Y, Pinter A, Nanthakumar K, Calzavara AJ, Austin PC, Tu JV, Lee DS. Sex differences in implantable cardioverter-defibrillator outcomes: Findings from a prospective defibrillator database. *Ann Intern Med*.; 156(3):195-203, 2012.

Eicher JC, Laurent G, Mathé A, Barthez O, Bertaux G, Philip JL, **Dorian P**, Wolf JE. Atrial dyssynchrony syndrome: an overlooked phenomenon and a potential cause of 'diastolic' heart failure. *Eur J Heart Fail*. 2012 Jan 29 [Epub ahead of print].

Endrenyi L

Zhang N, Yang J, Chow SC, **Endrenyi L**, Chi E. Impact of variability on the choice of biosimilarity limits in assessing follow-on biologics. *Stat Med*. 10;32(3):424-33. Epub 2012.

Endrenyi L, Chang C, Chow SC, Tothfalusi L. On the interchangeability of biologic drug products. *Stat Med*.; 10;32(3):434-41, 2012.

Endrenyi L, Tothfalusi L. Metrics for the evaluation of bioequivalence of modified-release formulations. *AAPS J*.; 14(4):813-9, 2012.

Chow SC, **Endrenyi L**, Lachenbruch PA. Comments on the FDA draft guidance on biosimilar products. *Stat Med*.; 10;32(3):364-9, 2012.

Shram MJ, Quinn AM, Chen N, Faulknor J, Luong D, Sellers EM, **Endrenyi L**. Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate

formulations in Canada: examination of current bioequivalence criteria. *Clin Ther.*; 34(5):1170-81, 2012.

Claxton R, Cook J, **Endrenyi L**, Lucas A, Martinez MN, Sutton SC. Estimating product bioequivalence for highly variable veterinary drugs. *J Vet Pharmacol Ther.*; 35 Suppl 1:11-6, 2012.

Chow SC, Wang J, **Endrenyi L**, Lachenbruch PA. Scientific considerations for assessing biosimilar products. *Stat Med.*; 10; 32(3):370-81, 2012.

Finkelstein Y

Schechter T, A Kirton, Laughlin S, Pontigon AM, **Finkelstein Y**, Macgregor D, Chan A, Deveber G, Brandão LR. Safety of anticoagulants in children with arterial ischemic stroke. *Blood.*; 119(4):949-56, 2012.

Schechter T, **Finkelstein Y**, Lim A, Kahr W, Williams S, Chan AL, Deveber G, Brandao LR. Unfractionated heparin dosing in young infants: clinical outcomes in a cohort monitored by Anti-Xa levels. *J Thromb Hemost.*; 10(3):368-74, 2012.

Finkelstein Y, Hutson JR, Wax P, Brent J. Toxicology-Surveillance of infant and Toddler poisoning in the United States: use of the Toxicology Investigators Consortium (ToxIC) Registry. *J Med Toxicol.*; 8(3):263-6, 2012.

Wiegand TJ, Wax PM, Schwartz T, **Finkelstein Y**, Gorodetsky R, Brent J; On Behalf of the Toxicology Investigators Consortium Case Registry Investigators. The Toxicology Investigator Consortium Case Registry: The 2011 Experience. *J Med Toxicol.*; 8(4):360-77, 2012.

Hutson JR, Weitzman S, Schechter T, Arceci RJ, Kim RB, **Finkelstein Y**. Pharmacokinetic and pharmacogenetic determinants and considerations in chemotherapy selection and dosing in infants. *Exp Opin Drug Metab Toxicol.* 8(6): 709-22, 2012.

Moretti ME, Koren G, **Finkelstein Y**. Methotrexate in misdiagnosed ectopic pregnancies. *Am J Obstet Gynecol.* 206(3): e13, 2012.

George SR

Novak G, Fan T, O'Dowd BF, **George SR**. Striatal development involves a switch in gene expression networks, followed by a myelination event: implications for neuropsychiatric disease. *Synapse.*; 67(4):179-88, 2012.

Perreault ML, Hasbi A, Alijaniam M, O'Dowd BF, **George SR**. Reduced striatal dopamine D1-D2 receptor heteromer expression and behavioural subsensitivity in juvenile rats. *Neuroscience.*; 6225:130-9, 2012.

Perreault ML, Jones-Tabah J, O'Dowd BF, **George SR**. A physiological role for the dopamine D5 receptor as a regulator of BDNF and Akt signalling in rodent prefrontal cortex. *Int J Neuropsychopharmacol.*; 16(2):477-83, 2012.

O'Dowd BF, Ji X, O'Dowd PB, Nguyen T, **George SR**. Disruption of the mu-delta opioid receptor heteromer. *Biochem Biophys Res Commun.*; 422(4):556-60, 2012.

Perreault ML, Fan T, Alijaniam M, O'Dowd BF, **George SR**. Dopamine D1-D2 receptor heteromer in dual phenotype GABA/glutamate-coexpressing striatal medium spiny neurons: regulation of BDNF, GAD67 and VGLUT1/2. *PLoS One.*; 7(3):e33348, 2012.

Grieder TE, George O, Tan H, **George SR**, Le Foll B, Laviolette SR, van der Kooy D. Phasic D1 and tonic D2 dopamine receptor signaling double dissociate the motivational effects of acute nicotine and chronic nicotine withdrawal. *Proc Natl Acad Sci U S A.*; 109(8):3101-6, 2012.

O'Dowd BF, Ji X, Nguyen T, **George SR**. Two amino acids in each of D1 and D2 dopamine receptor cytoplasmic regions are involved in D1-D2 heteromer formation. *Biochem Biophys Res Commun.*; 417(1):23-8, 2012.

Goldstein BI

McIntyre RS, Alsuwaidan M, **Goldstein BI**, Taylor VH, Schaffer A, Beaulieu S, Kemp DE; Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders. *Ann Clin Psychiatry.*; 24(1):69-81, 2012.

Schaffer A, McIntosh D, **Goldstein BI**, Rector NA, McIntyre RS, Beaulieu S, Swinson R, Yatham LN; Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force. The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. *Ann Clin Psychiatry.*; 24(1):6-22, 2012.

Sala R, Axelson DA, Castro-Fornieles J, Goldstein TR, **Goldstein BI**, Ha W, Liao F, Gill MK, Iyengar S, Strober MA, Yen S, Hower H, Hunt JI, Dickstein DP, Ryan ND, Keller MB, Birmaher B. Factors associated with the persistence and onset of new anxiety disorders in youth with bipolar spectrum disorders. *J Clin Psychiatry.*; 73(1):87-94, 2012.

Goldstein BI. Recent progress in understanding pediatric bipolar disorder. *Arch Pediatr Adolesc Med.*; 166(4):362-71, 2012.

Goldstein TR, Ha W, Axelson DA, **Goldstein BI**, Liao F, Gill MK, Ryan ND, Yen S, Hunt J, Hower H, Keller M, Strober M, Birmaher B. Predictors of prospectively examined suicide attempts among youth with bipolar disorder. *Arch Gen Psychiatry.*; 69(11):1113-22, 2012.

Goldstein BI, Birmaher B. Prevalence, Clinical Presentation and Differential Diagnosis of Pediatric Bipolar Disorder. *Isr J Psychiatry Relat Sci.*; 49(1):3-14, 2012.

Sala R, **Goldstein BI**, Morcillo C, Liu SM, Castellanos M, Blanco C. Course of comorbid anxiety disorders among adults with bipolar disorder in the U.S. population. *J Psychiatr Res.*; 46(7):865-72, 2012.

Goldstein BI, Sassi R, Diler RS. Pharmacologic treatment of bipolar disorder in children and adolescents. *Child Adolesc Psychiatr Clin N Am.*; 21(4):911-39, 2012.

Ballester J, Goldstein T, **Goldstein B**, Obreja M, Axelson D, Monk K, Hickey M, Iyengar S, Farchione T, Kupfer DJ, Brent D, Birmaher B. Is bipolar disorder specifically associated with aggression? *Bipolar Disord*; 14(3):283-90, 2012.

Bega S, Schaffer A, **Goldstein B**, Levitt A. Differentiating between Bipolar Disorder types I and II: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). *J Affect Disord.*; 138(1-2):46-53, 2012.

Grant DM

Wang S, Sugamori KS, Brenneman D, Hsu I, Calce A, **Grant DM**. Influence of arylamine N-acetyltransferase, sex, and age on 4-aminobiphenyl-induced in vivo mutant frequencies and spectra in mouse liver. *Environ Mol Mutagen.*;53(5):350-7, 2012.

Sugamori KS, Brenneman D, Sanchez O, Doll MA, Hein DW, Pierce WM Jr, **Grant DM**. Reduced 4-aminobiphenyl-induced liver tumorigenicity but not DNA damage in arylamine N-acetyltransferase null mice. *Cancer Lett.* 28;318(2):206-13., 2012.

Haas DA

Montalli VA, de Cássia Bergamaschi C, Rammaciato JC, Nolasco FP, Groppo FC, de Brito RB, **Haas DA**, Motta RH. The effect of smoking on the bioavailability of metronidazole in plasma and saliva. *Journal of the American Dental Association* 143(2):149-156, 2012.

Hampson D

Hampson DR, Gholizadeh S, Pacey LK. Pathways to drug development for autism spectrum disorders. *Clin Pharmacol Ther.*;91(2):189-200, 2012.

Tharmalingam S, Burns AR, Roy PJ, **Hampson DR**. Orthosteric and allosteric drug binding sites in the *Caenorhabditis elegans* mgl-2 metabotropic glutamate receptor. *europarmacology.*;63(4):667-74, 2012.

Antflick JE, **Hampson DR**. Modulation of glutamate release from parallel fibers by mGlu4 and pre-synaptic GABA(A) receptors. *J Neurochem.*; 120(4):552-63, 2012.

Higgins G

Silenieks LB, Koch E, **Higgins GA**. Silexan, an essential oil from flowers of *Lavandula angustifolia*, is not recognized as benzodiazepine-like in rats trained to discriminate a diazepam cue. *Phytomedicine*. 15;20(2):172-7, 2012.

Fletcher PJ, Soko AD, **Higgins GA**. Impulsive action in the 5-choice serial reaction time test in 5-HT_{2c} receptor null mutant mice. *Psychopharmacology (Berl)*; 226(3):561-70, 2012.

Duffy RA, Morgan C, Naylor R, **Higgins GA**, Varty GB, Lachowicz JE, Parker EM. Rolapitant (SCH 619734): a potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets. *Pharmacol Biochem Behav.*; 102(1):95-100, 2012.

Fletcher PJ, Rizos Z, Noble K, Soko AD, Silenieks LB, Lê AD, **Higgins GA**. Effects of the 5-HT_{2C} receptor agonist Ro60-0175 and the 5-HT_{2A} receptor antagonist M100907 on nicotine self-administration and reinstatement. *Neuropharmacology*; 62(7):2288-98, 2012.

Higgins GA, Silenieks LB, Rossmann A, Rizos Z, Noble K, Soko AD, Fletcher PJ. The 5-HT_{2C} receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control. *Neuropsychopharmacology*; 37(5):1177-91, 2012.

Ito S

Bozzo P, Koren G, **Ito S**. Health Canada advisory on domperidone should I avoid prescribing domperidone to women to increase milk production [corrected]? *Can Fam Physician.*; 58(9):952-3. Erratum in: *Can Fam Physician.*; 58(10):1085, 2012.

Asztalos EV, Campbell-Yeo M, daSilva OP, Kiss A, Knoppert DC, **Ito S**. Enhancing breast milk production with Domperidone in mothers of preterm neonates (EMPOWER trial). *BMC Pregnancy Childbirth.*; 31;12:87, 2012.

Butte A, **Ito S**. Translational bioinformatics: data-driven drug discovery and development. *Clin Pharmacol Ther.*; 91:949-52, 2012

Ito S, Nakamura H, Kobayashi T. Pediatric pharmacology in Japan. *Pediatr Drugs.*; 14: 247-249, 2012.

Wu A, Dalvi P, Lu X, Yang MD, Riddick D, Matthews J, Clevenger CV, Ross DD, Harper PA, **Ito S**. Induction of multidrug resistance transporter ABCG2 by prolactin in human breast cancer cells. *Mol Pharmacol (in press)*: Fastforward online publication: Nov 13, 2012.

Kalant H

Kalant H and Porath-Waller AJ. Clearing the Smoke on Cannabis, No. 5: Medical Uses of Cannabis and Cannabinoids. Ottawa, Canadian Centre on Substance Abuse. July, 2012.

Kalant H. Effects of Cannabis and Cannabinoids in the Human Nervous System. In: *The Effects of Drug Abuse on the Human Nervous System*; B. Madras and M.J. Kuhar (Eds.) 2012, Neuroscience-Net, LLC, www.neuroscience.com.

Kish SJ

Rusjan PM, Wilson AA, Mizrahi R, Boileau I, Chavez SE, Lobaugh NJ, **Kish SJ**, Houle S, Tong J. Mapping human brain fatty acid amide hydrolase activity with PET. *J Cereb Blood Flow Metab.*; 33(3):407-14, 2012.

Callaghan RC, Cunningham JK, Verdichevski M, Sykes J, Jaffer SR, **Kish SJ**. All-cause mortality among individuals with disorders related to the use of methamphetamine: a comparative cohort study. *Drug Alcohol Depend.*; 125(3):290-4, 2012.

Boileau I, Payer D, Houle S, Behzadi A, Rusjan PM, Tong J, Wilkins D, Selby P, George TP, Zack M, Furukawa Y, McCluskey T, Wilson AA, **Kish SJ**. Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. *J Neurosci*; 32(4):1353-9, 2012.

Callaghan RC, Cunningham JK, Allebeck P, Arenovich T, Sajeev G, Remington G, Boileau I, **Kish SJ**. Methamphetamine use and schizophrenia: a population-based cohort study in California. *Am J Psychiatry.*; 169(4):389-96, 2012.

Sacher J, Rabiner EA, Clark M, Rusjan P, Soliman A, Boskovic R, **Kish SJ**, Wilson AA, Houle S, Meyer JH. Dynamic, adaptive changes in MAO-A binding after alterations in substrate availability: an in vivo [(11)C]-harmine positron emission tomography study. *J Cereb Blood Flow Metab.*; 32(3):443-6, 2012.

Mann A, Miksys SL, Gaedigk A, **Kish SJ**, Mash DC, Tyndale RF. The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson's disease patients. *Neurobiol Aging.*; 33(9):2160-71, 2012.

Callaghan RC, Cunningham JK, Sykes J, **Kish SJ**. Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. *Drug Alcohol Depend.*; 120(1-3):35-40, 2012.

Koren G (84)

Koren G, Nordeng H. SSRIs and persistent pulmonary hypertension of the newborn. *BMJ*; 344:d7642, 2012.

Moretti ME, Caprara D, Drehuta I, Yeung E, Cheung S, Federico L, **Koren G**. The fetal safety of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. *Obstet Gynecol Int*; 658310, 2012.

Gedeon C, Nava-Ocampo AA, **Koren G**. Ethical issues in pharmacologic research in women undergoing pregnancy termination: a systemic review and survey of researchers. *Obstet Gynecol Int*.; 724591, 2012.

Walfisch A, Matok I, Sermer C, **Koren G**. Weight-depression association in a high-risk maternal population. *J Matern Fetal Neonatal Med*; 25: 1017-20, 2012.

Levy A, Matok I, Gorodischer R, Sherf M, Wiznitzer A, Uziel E, **Koren G**. Bias toward the null hypothesis in pregnancy drug studies that do not include data on medical terminations of pregnancy: the folic acid antagonists. *J Clin Pharmacol*; 52:78-83, 2012.

Hanly LN, Chen N, Aleksa K, Cutler M, Bajcetic M, Palassery R, Regueira O, Turner C, Baw B, Malkin B, Freeman D, Rieder MJ, Vasylyeva TL, **Koren G**. N-acetylcysteine as a novel prophylactic treatment for ifosfamide-induced nephrotoxicity in children: translational pharmacokinetics. *J Clin Pharmacol*; 52: 55-64, 2012.

Klieger-Grossmann C, Weitzner B, Panchaud A, Pistelli A, Einarson T, **Koren G**, Einarson A. Pregnancy outcomes following use of escitalopram: a prospective comparative cohort study. *J Clin Pharmacol*; 52: 766-70, 2012.

Aleksa K, Walasek P, Fulga N, Kapur B, Gareri J, **Koren G**. Simultaneous detection of seventeen drugs of abuse and metabolites in hair using solid phase micro extraction (SPME) with GC/MS. *Forensic Sci Int*; 218: 31-6, 2012.

Matok I, Levy A, Wiznitzer A, Uziel E, **Koren G**, Gorodischer R. The safety of fetal exposure to proton-pump inhibitors during pregnancy. *Dig Dis Sci*; 57: 699-705, 2012.

Russell E, **Koren G**, Rieder M, Van Uum S. Hair cortisol as a biological marker of chronic stress: current status, future directions and unanswered questions. *Psychoneuroendocrinology*; 37: 589-601, 2012.

Lam J, Kelly L, Ciszkowski C, Landsmeer ML, Nauta M, Carleton BC, Hayden MR, Madadi P, **Koren G**. Central nervous system depression of neonates breastfed by mothers receiving oxycodone for postpartum analgesia. *J Pediatr*; 160: 33-7, 2012.

Schwarz EB, Parisi SM, Handler SM, **Koren G**, Cohen ED, Shevchik GJ, Fischer GS. Clinical Decision Support to Promote Safe Prescribing to Women of Reproductive Age: A Cluster-Randomized Trial. *J Gen Intern Med* 2012; Feb 2.[Epub ahead of print]

Koren G, Nulman I, Aleksa K, Gareri J, Einarson A, Ito S; Motherisk Program. Essay for the 2011 CIHR/CMAJ award: Motherisk--caring for mothers, protecting the unborn. *CMAJ*; 7: 184: E155-7, 2012.

Al-Maawali A, Walfisch A, **Koren G**. Taking angiotensin-converting enzyme inhibitors during pregnancy: is it safe? *Can Fam Physician*; 58: 49-51, 2012.

Malone M, **Koren G**. Alcohol-induced behavioural problems in fetal alcohol spectrum disorders versus confounding behavioural problems. *J Popul Ther Clin Pharmacol*; 19: e32-40, 2012.

Lanctôt KL

Mitchell I, Paes B, Li A, **Lanctôt KL**. CARESS: The Canadian Registry of Palivizumab [letter]. *Pediatr Infect Dis J*.; 31(2):213, 2012.

Sinyor M, Schaffer A, Smart KA, Levitt AJ, **Lanctôt KL**, Grysman NH. Sponsorship, antidepressant dose and outcome in major depressive disorder: meta-analysis of randomized controlled trials. *J Clin Psychiat*; 73(2):e277-e287, 2012.

Levy K, **Lanctôt KL**, Farber S, Li A, Herrmann N. Does treating neuropsychiatric symptoms in Alzheimer's disease relieve caregiver burden? *Drugs Aging* 29(3):167-79, 2012.

Paes B, Mitchell I, Li A, **Lanctôt KL**. Respiratory syncytial virus prophylaxis and hospitalisations in special populations. *Eur J Pediatr*; 171(5): 833-41, 2012. Erratum ;171(9):1419 [Epub 2011 Dec 28 10.1007/s00431-011-1654-8].

Swardfager WL, Herrmann N, Cornish S, Mazereeuw G, Marzolini S, Sham L, **Lanctôt KL**. Exercise and inflammatory markers in coronary artery disease: a meta-analysis. *Am Heart J*; 163(4):666-676.e3, 2012.

Mazereeuw G, **Lanctôt KL**, Chau SA, Swardfager WL, Herrmann N. Effects of omega-3 fatty acids on cognitive performance: a meta-analysis. *Neurobiol Aging*.; 33: 1482.e17–1482.e29. [Epub ahead of print 2012-Feb- 3].

Herrmann N, Black SE, Chow T, Cappell J, Tang-Wai DF, **Lanctôt KL**. Serotonergic function and treatment of behavioural and psychological symptoms of frontotemporal dementia. *Am J Geriatr Psychiat*; 20(9):789-797, 2012. [Epub ahead of print 2011 Nov 4].

Paes B, Mitchell I, Li A, **Lanctôt KL**, The CARESS Investigators. A comparative study of Respiratory Syncytial Virus (RSV) prophylaxis in premature infants with the Canadian Registry (CARESS). *Eur J Clin Microbiol Infect Dis*.; 31(10):2703-11 [Epub ahead of print 2012 May 1].

Lapshin H, **Lanctôt KL**, O'Connor P, Feinstein A. Computerized cognitive testing for patients with multiple sclerosis. *Multiple Sclerosis and Related Disorders*; 1(4): 196-201 [epub ahead of print 2012 May 29].

Hussman JM, Li A, Paes B, **Lanctôt KL**. A review of cost-effectiveness of palivizumab for respiratory syncytial virus. *Expert Rev Pharmacoecon Outcomes Res*; 12(5):553-, 2012.

Drye LT, Scherer RW, **Lanctôt KL**, Rosenberg PB, Herrmann N, Bachman D, Mintzer JE for the ADMET Research Group. Designing a trial to evaluate potential treatments for apathy in dementia: the Apathy in Dementia Methylphenidate trial (ADMET). *Am J Geriatr Psychiat* 2012 Apr 4. [Epub ahead of print].

Noel-Storr AH, Flicker L, Ritchie CW, Nguyen G, Gupta T, Wood P, Walton J, Desai M, Fraser Solomon D, Molena E, Worrall R, Hayen A, Choudhary P, Ladds E, **Lanctôt KL**, Verhey FR, Mead GE, Clare L, McCleery JM, Fioravanti M, Hyde C, Marcus S, McShane R. Systematic review of the body of evidence for use of biomarkers in the diagnosis of dementia. *Alzheimers Dement*. 27 [epub ahead of print], 2012.

Laposa RR

Wong JC, Visanji NP, Dabek MK, **Laposa RR**, Hazrati LN. Dendritic spine density is altered in a mouse model of Cockayne syndrome. *Neuropathol Appl Neurobiol*. 2012 Oct 5. doi: 10.1111/j.1365-2990.2012.01305.x. [Epub ahead of print].

Sacco R, Tamblyn L, Rajakulendran N, Bralha FN, Tropepe V, **Laposa RR**. Cockayne syndrome b maintains neural precursor function. *DNA Repair (Amst)*.; 12(2):110-20, 2012.

Le AD

Fletcher PJ, Rizos Z, Noble K, Soko AD, Silenieks LB, **Lê AD**, Higgins GA. *Neuropharmacology*. Effects of the 5-HT_{2C} receptor agonist Ro60-0175 and the 5-HT_{2A} receptor antagonist M100907 on nicotine self-administration and reinstatement.; 62(7):2288-98, 2012.

Li S, Li Z, Pei L, **Le AD**, Liu F.. *J Exp Med*. The $\alpha 7$ nACh-NMDA receptor complex is involved in cue-induced reinstatement of nicotine seeking, 19;209(12):2141-7, 2012.

Le Foll B

Pushparaj A, Pryslawsky Y, Forget B, Yan Y, **Le Foll B**. Extinction bursts in rats trained to self-administer nicotine or food in 1-h daily sessions. *Am J Transl Res*. 4(4):422-31, 2012.

Lev-Ran S, Imtiaz S, **Le Foll B**. Self-reported psychotic disorders among individuals with substance use disorder. *American Journal on Addictions*. 21(6):531-5, 2012

Teo C, Zai C, Borlido C, Tomasetti C, Strauss J, Shinkai T, **Le Foll B**, Wong A, Kennedy JL, De Luca V. Analysis of treatment-resistant schizophrenia and 384 markers from candidate genes. *Pharmacogenet Genomics*. 22(11):807-11, 2012.

Lev-Ran S, **Le Foll B**, McKenzie K, Rehm J. Cannabis use and mental health-related quality of life among individuals with anxiety disorders. *J Anxiety Disord*. 26(8):799-81, 2012.

Lev-Ran S, Balchand K, Lefebvre L, Farid Araki K, **Le Foll B**. Pharmacotherapy of alcohol use disorders and co-morbid psychiatric disorders: a review. *Canadian Journal of Psychiatry*. 57(6):342-9, 2012.

Lev-Ran S, **Le Foll B**, Farid Araki K. A case of diagnosing a long psychotic disorder during medical withdrawal. *American Journal on Addictions*. 21(3):285-6, 2012.

Yan, Y, Pushparaj, A, Gamaledin, I, Steiner, R, Picciotto, M, Roder, J, **Le Foll, B**: Nicotine-taking and nicotine-seeking in C57Bl/6J mice without prior operant training or food restriction. *Behavioural Brain Research*. 230(1):34-9, 2012.

De Luca V, Zai C, de Souza R, Polsinelli G, Teo C, Shinkai T, Wong A, **Le Foll B**, Kennedy JL: Admixture analysis of Age at Onset in Schizophrenia: Genetic Association Study of 45 candidate loci. *Schizophr Res* 134(2-3):288-290, 2012.

Gamaledin I, Zvonok A, Makriyannis A, Goldberg SR, **Le Foll B**: Effects of a Selective Cannabinoid CB2 Agonist and Antagonist on Intravenous Nicotine Self Administration and Reinstatement of Nicotine Seeking. *PLoS One* 7(1):e29900, 2012.

Grieder TE, George O, Tan H, George SR, **Le Foll B**, Laviolette SR, van der Kooy D: Phasic D1 and tonic D2 dopamine receptor signaling double dissociate the motivational effects of acute nicotine and chronic nicotine withdrawal. *Proc Natl Acad Sci U S A*, 109(8):3101-6, 2012.

Yan Y, Pushparaj A, Le Strat Y, Gamaledin I, Barnes C, Justinova Z, Goldberg SR, **Le Foll B**. Blockade of dopamine D4 receptor attenuates reinstatement of extinguished nicotine-seeking behaviour in rats. *Neuropsychopharmacology*. 37(3):685-96, 2012.

Le Foll B, Chakraborty-Chatterjee M, Lev-Ran S, Barnes C, Pushparaj A, Gamaledin, I, Yan Y, Khaled M, Goldberg SR. Varenicline decreases nicotine self administration and nicotine- and cue-induced reinstatement of nicotine-seeking behavior in rats when a long pretreatment time is used. *International Journal of Neuropsychopharmacology*, 15(9):1265-74, 2-012.

Li PP

Roedding AS, Gao AF, Au-Yeung W, Scarcelli T, **Li PP**, Warsh JJ. Effect of oxidative stress on TRPM2 and TRPC3 channels in B lymphoblast cells in bipolar disorder. *Bipolar Disord*. 14(2):151-61, 2012.

Matthews J

Lo R, **Matthews J**. High-resolution genome-wide mapping of AHR and ARNT binding sites by ChIP-Seq. *Toxicol Sci.*; 130(2):349-61, 2012.

Ahmed S, Al-Saigh S, **Matthews J**. FOXA1 is essential for aryl hydrocarbon receptor-dependent regulation of cyclin G2. *Mol Cancer Res.*; 10(5):636-48, 2012.

McIntyre RS

Mansur RB, Cha DS, Asevedo E, **McIntyre RS**, Brietzke E. Selfish brain and neuroprogression in bipolar disorder. *Prog Neuropsychopharmacol Biol Psychiatry*. 2013 Jun 3;43:66-71. Epub 2012 Dec 20. PubMed. PMID: 23266709.

Kudlow PA, Cha DS, **McIntyre RS**. Predicting treatment response in major depressive disorder: the impact of early symptomatic improvement. *Can J Psychiatry*.; 57(12):782-8, 2012. Review. PubMed PMID: 23228238.

McIntyre RS, Soczynska JK, Woldeyohannes HO, Miranda A, Vaccarino A, Macqueen G, Lewis GF, Kennedy SH. A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder. *Bipolar Disord.*;14(7):697-706, 2012.

McIntyre RS, Powell AM, Kaidanovich-Beilin O, Soczynska JK, Alsuwaidan M, Woldeyohannes HO, Kim AS, Gallagher LA. The neuroprotective effects of GLP-1: possible treatments for cognitive deficits in individuals with mood disorders. *Behav Brain Res*. 15;237:164-71. Epub, 2012. Review. PubMed PMID: 23000536.

Soczynska JK, Mansur RB, Brietzke E, Swardfager W, Kennedy SH, Woldeyohannes HO, Powell AM, Manierka MS, **McIntyre RS**. Novel therapeutic targets in depression: minocycline as a candidate treatment. *Behav Brain Res*. 1;235(2):302-17, 2012.

Castelo MS, Hyphantis TN, Macêdo DS, Lemos GO, Machado YO, Kapczinski F, **McIntyre RS**, Carvalho AF. Screening for bipolar disorder in the primary care: a Brazilian survey. *J Affect Disord*. 20;143(1-3):118-24, 2012.

Zhu T, De Luca V, Gallagher LA, Woldeyohannes HO, Soczynska JK, Szymkowitz S, Muzina DJ, Kennedy SH, **McIntyre RS**. Admixture analysis of age at onset in major depressive disorder. *Gen Hosp Psychiatry*.; 34(6):686-91, 2012.

Macêdo DS, Medeiros CD, Cordeiro RC, Sousa FC, Santos JV, Morais TA, Hyphantis TN, **McIntyre RS**, Quevedo J, Carvalho AF. Effects of alpha-lipoic acid in an animal model of mania induced by D-amphetamine. *Bipolar Disord.*; 14(7):707-18, 2012.

McIntyre RS, Soczynska JK, Liauw SS, Woldeyohannes HO, Brietzke E, Nathanson J, Alsuwaidan M, Muzina DJ, Taylor VH, Cha DS, Kennedy SH. The association between childhood adversity and components of metabolic syndrome in adults with mood disorders: results from the international mood disorders collaborative project. *Int J Psychiatry Med.*; 43(2):165-77, 2012.

Kaidanovich-Beilin O, Cha DS, **McIntyre RS**. Crosstalk between metabolic and neuropsychiatric disorders. *F1000 Biol Rep.*; 4:14, 2012.

McIntyre RS. The atypical antipsychotic class of psychotropic agents. Foreword. *Expert Opin Pharmacother.*; 13(11):i-ii. , 2012.

Brietzke E, Mansur RB, Soczynska J, Powell AM, **McIntyre RS**. A theoretical framework informing research about the role of stress in the pathophysiology of bipolar disorder. *Prog Neuropsychopharmacol Biol Psychiatry*.; 39(1):1-8, 2012.

Jerrell JM, Tripathi A, Rizvi AA, **McIntyre RS**. The risk of developing type 2 diabetes mellitus associated with psychotropic drug use in children and adolescents: a retrospective cohort analysis. *Prim Care Companion CNS Disord.*; 14(1), 2012.

Baskaran A, Milev R, **McIntyre RS**. The neurobiology of the EEG biomarker as a predictor of treatment response in depression. *Neuropharmacology*.; 63(4):507-132012.

McIntyre RS, Rosenbluth M, Ramasubbu R, Bond DJ, Taylor VH, Beaulieu S, Schaffer A; Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force. Managing medical and psychiatric comorbidity in individuals with major depressive disorder and bipolar disorder. *Ann Clin Psychiatry*.; 24(2):163-92012.

McIntyre RS, Cha DS, Alsuwaidan M, McIntosh D, Powell AM, Jerrell JM. A review of published evidence reporting on the efficacy and pharmacology of lurasidone. *Expert Opin Pharmacother.*; 13(11):1653-9, 2012.

McIntyre RS, Yoon J. Efficacy of antimanic treatments in mixed states. *Bipolar Disord.*; 14 Suppl 2:22-36, 2012.

Brietzke E, Mansur RB, Soczynska JK, Kapczinski F, Bressan RA, **McIntyre RS**. Towards a multifactorial approach for prediction of bipolar disorder in at risk populations. *J Affect Disord.*;140(1):82-91, 2012.

Jerrell JM, **McIntyre RS**, Black GB. Economic grand rounds: economic costs of failure to monitor adverse effects of second-generation antipsychotics: an underestimated factor. *Psychiatr Serv.*; 63(3):202-4, 2012.

Brietzke E, Mansur RB, Grassi-Oliveira R, Soczynska JK, **McIntyre RS**. Inflammatory cytokines as an underlying mechanism of the comorbidity between bipolar disorder and migraine. *Med Hypotheses*.; 78(5):601-5, 2012.

Cha DS, **McIntyre RS**. Treatment-emergent adverse events associated with atypical antipsychotics. *Expert Opin Pharmacother.*; 13(11):1587-98. Epub 2012 Feb 5. Review. PubMed PMID: 22304541.

McPherson JP

Ondovcik SL, Tamblyn L, **McPherson JP**, Wells PG. Oxoguanine glycosylase 1 (OGG1) protects cells from DNA double-strand break damage following methylmercury (MeHg) exposure. *Toxicol Sci*. 2012 Jul;128(1):272-83. doi: 10.1093/toxsci/kfs138. Epub 2012 Apr 20.

Meyer JH

Soliman A, Udemgba C, Fan I, Xu X, Miler L, Rusjan P, Houle S, Wilson AA, Pruessner J, Ou XM, **Meyer JH**. Convergent effects of acute stress and glucocorticoid exposure upon MAO-A in humans. *J Neurosci.*; 32(48):17120-7, 2012.

Meyer JH. Neuroimaging High Risk States for Suicide. In: Dwivedi Y, editor. *The Neurobiological Basis of Suicide*. Boca Raton (FL): CRC Press; 2012. Chapter 9.

Meyer JH. Neuroimaging markers of cellular function in major depressive disorder: implications for therapeutics, personalized medicine, and prevention. *Clin Pharmacol Ther.*; 91(2):201-14, 2012.

Sacher J, Rabiner EA, Clark M, Rusjan P, Soliman A, Boskovic R, Kish SJ, Wilson AA, Houle S, **Meyer JH**. Dynamic, adaptive changes in MAO-A binding after alterations in substrate availability: an in vivo [(11)C]-harmine positron emission tomography study. *J Cereb Blood Flow Metab.*; 32(3):443-6. Doi, 2012.

Grunewald M, Johnson S, Lu D, Wang Z, Lomber G, Albert PR, Stockmeier CA, **Meyer JH**, Urrutia R, Miczek KA, Austin MC, Wang J, Paul IA, Woolverton WL, Seo S, Sittman DB, Ou XM. Mechanistic role for a novel glucocorticoid-KLF11 (TIEG2) protein pathway in stress-induced monoamine oxidase A expression. *J Biol Chem.*; 287(29):24195-206, 2012.

Milgram NW

Pan Y, Araujo JA, Burrows J, de Rivera C, Gore A, Bhatnagar S, **Milgram NW**. Cognitive enhancement in middle-aged and old cats with dietary supplementation with a nutrient blend containing fish oil, B vitamins, antioxidants and arginine. *Br J Nutr.* 2012 Dec 5:1-10. [Epub ahead of print]

Zicker SC, Jewell DE, Yamka RM, **Milgram NW**. Evaluation of cognitive learning, memory, psychomotor, immunologic, and retinal functions in healthy puppies fed foods fortified with docosahexaenoic acid-rich fish oil from 8 to 52 weeks of age. *J Am Vet Med Assoc.*; 241(5):583-94, 2012.

Snigdha S, Christie LA, De Rivera C, Araujo JA, **Milgram NW**, Cotman CW. Age and distraction are determinants of performance on a novel visual search task in aged Beagle dogs. *Age (Dordr.)*; 34(1):67-73, 2012.

Mittmann N

Mittmann N, Isogai PK, Saskin R, Liu N, Porter J, Cheung MC, Leighl NB, Hoch J, Trudeau ME, Evans WK, Dainty K, Earle C. Population-based home care services in breast cancer: resources and costs. *Current Oncology.*; 19(6): e383-391, 2012.

Mittmann N, Seung SJ, Hill MD, Phillips SJ, Hachinski V, Coté R, Buck BH, Mackey A, Gladstone DJ, Howse DC, Shuaib A, Sharma M. Impact of disability status on ischemic stroke costs in Canada in the first year. *Canadian Journal of Neurological Sciences*; 39(6): 793-800, 2012.

Mittmann N, Koo M, Daneman N, McDonald A, Baker M, Matlow A, Krahn M, Shojania K, Etchells E. The Economic burden of patient safety targets in acute care. *Drug Healthcare and Patient Safety*; 4: 141-165, 2012.

Craven BC, Hitzig SL, **Mittmann N**. Impact of impairment and secondary health conditions on health preference among individuals with chronic spinal cord injury. *Journal of Spinal Cord Medicine*; 35(6): 361-370, 2012.

Isogai PK, Rueda S, Rachlis AR, Rourke SB, **Mittmann N**. Prediction of health preference values from CD4 counts in individuals with HIV. *Medical Decision Making* (accepted April 2012). Epublication 8 August 2012; DOI: 10.1177/0272989X12453499

Chan B, Nanwa N, **Mittmann N**, Bryant D, Coyte P, Houghton P. The average cost of pressure ulcer management in a community dwelling spinal cord injury population. *International Wound Journal*. June 21, 2012 DOI: 10.1111/j.1742-481X.2012.01002.x epub ahead of print.

Lathia N, **Mittmann N**, DeAngelis C, Isogai PK, Hoch JS, Cheung MC, Walker SE. Eliciting Patient Preferences for Outpatient Treatment of Febrile Neutropenia: A Discrete Choice Experiment Supportive Care in Cancer. 2012 Jun 9 Epublication ahead of print DOI: 10.1007/s00520-012-1517-5

Rourke SB, Gardner S, Burchell AN, Major C, Rueda S, Waring V, Fisher M, Raboud J, DiPede T, Taylor D, Cooper C, Cairney J, Rachlis A, **Mittmann N**, Wobeser W, Salit IE, Loutfy M, Crouzat F, Bayoumi A, Gough K, Kilby D, Smieja M, Ralph E, Cohen J, Sandre R. Cohort Profile: The Ontario HIV Treatment Network Cohort Study (OCS). *International Journal of Epidemiology* 2012 Feb 16 Epublication ahead of print.

Etchells E, Koo M, Baker M, Krahn MD, McDonald A, Matlow A, Daneman N, **Mittmann N**. Comparative Economic Analyses of Patient Safety Improvement Strategies in Acute Care: A Systematic Review. *BMJ Quality & Safety*; 21(6):448-56, 2012.

Evans WK, Wolfson M, Oderkirk J, Flanagan WM, Shin J, Goffin J, Asakawa K., Earle C, **Mittmann N**, Fairclough L, Fines P, Gribble S, Hoch J, Hicks C, Omariba W, Ng E.. The evaluation of cancer control interventions in lung cancer using the Canadian Cancer Risk Management Model. *Lung Cancer Management*; 1(1): 25-33, 2012.

Mittmann N, Evans WK, Rocchi A, Longo CJ, Au H-J, Husereau D, Leighl N, Isogai P, Krahn M, Peacock S, Marshall D, Coyle D, Malfair Taylor SC, Jacobs P, Oh PI. Guidelines for health technologies: specific guidance for oncology products. *Value in Health*; 15(3): 580-85, 2012.

Mittmann N, Isogai PK, Connors JM, Rebeira M, Cheung M. Economic analysis of alemtuzumab (MabCampath) in fludarabine-refractory chronic lymphocytic leukemia. *Open Pharmacoeconomics and Health Economics Journal*; 4: 18-25, 2012.

Mittmann N, Knowles SR, Koo M, Shear NH, Rachlis AR, Rourke S. The incidence of toxic epidermal necrolysis and Stevens-Johnson syndrome in an HIV cohort. *American Journal of Clinical Dermatology*; 13(1): 49-54, 2012.

Nava-Ocampo A

Kim MW, Hong SC, Choi JS, Han JY, Oh MJ, Kim HJ, **Nava-Ocampo A**, Koren G. Homocysteine, folate and pregnancy outcomes. *J Obstet Gynaecol.*; 32(6):520-4, 2012.

Lee JE, Han JY, Choi JS, Ahn HK, Lee SW, Kim MH, Ryu HM, Yang JH, **Nava-Ocampo AA**, Koren G. Pregnancy outcome after exposure to the probiotic *Lactobacillus* in early pregnancy. *J Obstet Gynaecol.*; 32(3):227-9, 2012.

Gedeon C, **Nava-Ocampo AA**, Koren G. Ethical issues in pharmacologic research in women undergoing pregnancy termination: a systemic review and survey of researchers. *Obstet Gynecol Int.*; 724591, 2012.

Neuman MG

Neuman MG, McKinney KK, Nanau RM, Kong V, Malkiewicz I, Mazulli T, Moussa G, Cohen LB. Drug-induced severe adverse reaction enhanced by human herpes virus-6 reactivation. *Transl Res.* 2013 Jan 16. doi:pii: S1931-5244(12)00448-3. 10.1016/j.trsl.2012.12.012. [Epub ahead of print.

Nanau RM, **Neuman MG**. Nutritional and probiotic supplementation in colitis models. *Dig Dis Sci.*; 57(11):2786-810, 2012.

Neuman MG, Nanau RM. Single-nucleotide polymorphisms in inflammatory bowel disease. *Transl Res.*; 160(1):45-64, 2012.

Neuman MG, Nanau RM. Inflammatory bowel disease: role of diet, microbiota, life style. *Transl Res.*; 160(1):29-44, 2012.

Nanau RM, **Neuman MG**. Metabolome and inflammasome in inflammatory bowel disease. *Transl Res.*; 160(1):1-28, 2012.

Pritchett JC, Nanau RM, **Neuman MG**. The Link between Hypersensitivity Syndrome Reaction Development and Human Herpes Virus-6 Reactivation. *Int J Hepatol.*; 2012:723062. doi: 10.1155/2012/723062. Epub 2012 May 16.

Neuman MG, Schmilovitz-Weiss H, Hilzenrat N, Bourliere M, Marcellin P, Trepo C, Mazulli T, Moussa G, Patel A, Baig AA, Cohen L. Markers of inflammation and fibrosis in alcoholic hepatitis

and viral hepatitis C. *Int J Hepatol.* 2012;2012:231210. doi: 10.1155/2012/231210. Epub 2012 Feb 22.

Neuman MG, Schneider M, Nanau RM, Parry C. HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury. *Int J Hepatol.* 2012;2012:760706. doi: 10.1155/2012/760706. Epub 2012 Mar 11.

Neuman MG, Cohen L, Nanau RM, Hwang PA. Genetic and immune predictors for hypersensitivity syndrome to antiepileptic drugs. *Transl Res.*; 159(5):397-406, 2012.

Neuman MG, Schneider M, Nanau RM, Parry C. Alcohol Consumption, Progression of Disease and Other Comorbidities, and Responses to Antiretroviral Medication in People Living with HIV. *AIDS Res Treat.*; 2012:751827, 2012.

Neuman MG. Osteopontin biomarker in inflammatory bowel disease, animal models and target for drug discovery. *Dig Dis Sci.*; 57(6):1430-1, 2012..

Neuman MG, Schneider M, Nanau RM, Parry C, Chersich M. The relationship between alcohol consumption and HIV risk behavior: A systematic literature review of high risk groups, with a focus on South Africa. In: *Public Health - Social and Behavioral Health*. InTech Open Access Publisher, Rijeka, Croatia. 2012:243-292. ISBN 979-953-307-499-2.-e.

Nobrega JN

Hamani C, Giacobbe P, Diwan M, Balbino ES, Tong J, Bridgman A, Lipsman N, Lozano AM, Kennedy SH, **Nobrega JN**. Monoamine oxidase inhibitors potentiate the effects of deep brain stimulation. *Am J Psychiatry.* 169(12):1320-1, 2012.

Creed MC, Hamani C, **Nobrega JN**. Effects of repeated deep brain stimulation on depressive- and anxiety-like behavior in rats: Comparing entopeduncular and subthalamic nuclei. *Brain Stimul.* doi:pii: S1935-861X(12)00185-4. 10.1016/j.brs.2012.09.012. [Epub ahead of print], 2012.

Creed MC, Hamani C, Bridgman A, Fletcher PJ, **Nobrega JN**. Contribution of decreased serotonin release to the antidyskinetic effects of deep brain stimulation in a rodent model of tardive dyskinesia: comparison of the subthalamic and entopeduncular nuclei. *J Neurosci.*; 32(28):9574-81, 2012.

Hamani C, **Nobrega JN**. Preclinical studies modeling deep brain stimulation for depression. *Biol Psychiatry.*; 72(11):916-23, 2012.

Creed MC, Hamani C, **Nobrega JN**. Early gene mapping after deep brain stimulation in a rat model of tardive dyskinesia: comparison with transient local inactivation. *Eur Neuropsychopharmacol.*; 22(7):506-172012.

O'Brien PJ

Macallister SL, Martin-Brisac N, Lau V, Yang K, **O'Brien PJ**. Acrolein and chloroacetaldehyde: An examination of the cell and cell-free biomarkers of toxicity. *Chem Biol Interact*. 2012 Dec 7. doi:pii: S0009-2797(12)00261-X. [Epub ahead of print].

Lip H, Yang K, Macallister SL, **O'Brien PJ**. Glyoxal and methylglyoxal: Autoxidation from dihydroxyacetone and polyphenol cytoprotective antioxidant mechanisms. *Chem Biol Interact*. 2012 Dec 3. doi:pii: S0009-2797(12)00257-8. . [Epub ahead of print]

O'Dowd BF

Novak G, Fan T, **O'Dowd BF**, George SR. Striatal development involves a switch in gene expression networks, followed by a myelination event: implications for neuropsychiatric disease. *Synapse*.; 67(4):179-88, 2012.

Perreault ML, Hasbi A, Alijaniam M, **O'Dowd BF**, George SR. Reduced striatal dopamine D1-D2 receptor heteromer expression and behavioural subsensitivity in juvenile rats. *Neuroscience*.; 225:130-9, 2012.

Perreault ML, Jones-Tabah J, **O'Dowd BF**, George SR. A physiological role for the dopamine D5 receptor as a regulator of BDNF and Akt signalling in rodent prefrontal cortex. *Int J Neuropsychopharmacol*.; 16(2):477-83, 2012.

O'Dowd BF, Ji X, O'Dowd PB, Nguyen T, George SR. Disruption of the mu-delta opioid receptor heteromer. *Biochem Biophys Res Commun*.; 422(4):556-60,2012.

Perreault ML, Fan T, Alijaniam M, **O'Dowd BF**, George SR. Dopamine D1-D2 receptor heteromer in dual phenotype GABA/glutamate-coexpressing striatal medium spiny neurons: regulation of BDNF, GAD67 and VGLUT1/2. *PLoS One*.; 7(3):e33348, 2012.

O'Dowd BF, Ji X, Nguyen T, George SR. Two amino acids in each of D1 and D2 dopamine receptor cytoplasmic regions are involved in D1-D2 heteromer formation. *Biochem Biophys Res Commun*.; 417(1):23-8, 2012.

Okey AB

Prokopec SD, Watson JD, Waggott DM, Smith AB, Wu AH, **Okey AB**, Pohjanvirta R, Boutros PC. Systematic evaluation of medium-throughput mRNA abundance platforms. *RNA*.; 19(1):51-62, 2012.

Yao CQ, Prokopec SD, Watson JD, Pang R, P'ng C, Chong LC, Harding NJ, Pohjanvirta R, **Okey AB**, Boutros PC. Inter-strain heterogeneity in rat hepatic transcriptomic responses to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). *Toxicol Appl Pharmacol*.; 260(2):135-45, 2012.

Pang KS

Durk MR, Chan GN, Campos CR, Peart JC, Chow EC, Lee E, Cannon RE, Bendayan R, Miller DS, **Pang KS**. 1 α ,25-Dihydroxyvitamin D₃-liganded vitamin D receptor increases expression and transport activity of P-glycoprotein in isolated rat brain capillaries and human and rat brain microvessel endothelial cells. *J Neurochem.*; 123(6):944-53, 2012.

Chow EC, **Pang KS**. Why We Need Proper PBPK Models to Examine Intestine and Liver Oral Drug Absorption. *Curr Drug Metab.*; 14(1):57-79, 2012.

Pang KS, Chow EC. Commentary: theoretical predictions of flow effects on intestinal and systemic availability in physiologically based pharmacokinetic intestine models: the traditional model, segregated flow model, and QGut model. *Drug Metab Dispos.*; 40(10):1869-77, 2012.

Maeng HJ, Chapy H, Zaman S, **Pang KS**. Effects of 1 α ,25-dihydroxyvitamin D₃ on transport and metabolism of adefovir dipivoxil and its metabolites in Caco-2 cells. *Eur J Pharm Sci.*; 46(3):149-66, 2012.

Rostami-Hodjegan A, Tamai I, **Pang KS**. Physiologically based pharmacokinetic (PBPK) modeling: it is here to stay! *Biopharm Drug Dispos.*; 33(2):47-50, 2012.

Zhao P, Vieira M, Grillo JA, Song P, Wu TC, Zheng ZH, Arya V, Berglund E, Atkinson AJ, Jr, Sugiyama Y, **Pang KS**, Reynolds KS., Abernethy DR, Zhang L, Lesko LJ and Huang S M.: Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. *J. Clin. Pharmacol.* 52: 91S-108S, 2012.

Grillo JA, Zhao P, Bullock J, Choi YM, Booth BP, Lu M, Robie-Suh K, Berglund EG, **Pang KS**, Rahman N A, Zhang L, Lesko LJ and Huang SM.: Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario with rivaroxaban during the drug review process: implications for clinical practice. *Biopharm. Drug Dispos.* 33:99-110, 2012.

Park H-W

Anastasiou D, Yu Y, Israelsen WJ, Jiang JK, Boxer MB, Hong BS, Tempel W, Dimov S, Shen M, Jha A, Yang H, Mattaini KR, Metallo CM, Fiske BP, Courtney KD, Malstrom S, Khan TM, Kung C, Skoumbourdis AP, Veith H, Southall N, Walsh MJ, Brimacombe KR, Leister W, Lunt SY, Johnson ZR, Yen KE, Kunii K, Davidson SM, Christofk HR, Austin CP, Inglese J, Harris MH, Asara JM, Stephanopoulos G, Salituro FG, Jin S, Dang L, Auld DS, **Park HW**, Cantley LC, Thomas CJ, Vander Heiden MG. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. *Nature Chem Biol*, 8:839-847, 2012.

Visschedyk D, Rochon A, Tempel W, Dimov S, **Park HW**, Merrill AR. Certhrax toxin, an Anthrax-related ADP-ribosyltransferase from *Bacillus cereus*. *J Biol Chem*, 2012 Sep 19. [Epub ahead of print].

Dixon MJ, Gray A, Schenning M, Agacan M, Tempel W, Tong Y, Nedyalkova L, **Park HW**, Leslie NR, van Aalten DM, Downes CP, Batty IH. IQGAP proteins reveal an atypical phosphoinositide (aPI) binding domain with a pseudo C2 domain fold. *J Biol Chem.* 287:22483-22496, 2012.

Zhu H, Lee HY, Tong Y, Hong BS, Kim KP, Shen Y, Lim KJ, Mackenzie F, Tempel W, **Park HW**. Crystal structure of the tetratricopeptide repeat domains of kinesin light chains: Insight into cargo recognition mechanisms. *PLoS One.* 7:e33943, 2012.

Siddiqui N, Tempel W, Nedyalkova L, Volpon L, Wernimont AK, Osborne MJ, **Park HW**, Borden KL. Structural insights into the allosteric effects of 4EBP1 on the eukaryotic translation initiation factor eIF4E. *J Mol Biol.* 415:781-792, 2012.

Petronis A

Khare T, Pai S, Koncevicius K, Pal M, Kriukiene E, Liutkeviciute Z, Irimia M, Jia P, Ptak C, Xia M, Tice R, Tochigi M, Morera S, Nazarians A, Belsham D, Wong AH, Blencowe BJ, Wang SC, Kapranov P, Kustra R, Labrie V, Klimasauskas S, **Petronis A**. 5-hmC in the brain is abundant in synaptic genes and shows differences at the exon-intron boundary. *Nat Struct Mol Biol.* 19(10):1037-43, 2012.

Labrie V, Pai S, **Petronis A**. Epigenetics of major psychosis: progress, problems and perspectives. *Trends Genet.*; 28(9):427-35, 2012.

Cortese R, Kwan A, Lalonde E, Bryzgunova O, Bondar A, Wu Y, Gordevicius J, Park M, Oh G, Kaminsky Z, Tverkuvienė J, Laurinavicius A, Jankevicius F, Sendorek DH, Haider S, Wang SC, Jarmalaite S, Laktionov P, Boutros PC, **Petronis A**. Epigenetic markers of prostate cancer in plasma circulating DNA. *Hum Mol Genet.* 15;21(16):3619-31, 2012.

Kaminsky Z, Tochigi M, Jia P, Pal M, Mill J, Kwan A, Ioshikhes I, Vincent JB, Kennedy JL, Strauss J, Pai S, Wang SC, **Petronis A**. A multi-tissue analysis identifies HLA complex group 9 gene methylation differences in bipolar disorder. *Mol Psychiatry.*; 17(7):728-40, 2012.

Piquette-Miller M

Cressman AM, **Piquette-Miller M**. Epigenetics: a new link toward understanding human disease and drug response. *Clin Pharmacol Ther.*; 92(6):669-73. 2012.

Anger GJ, Cressman AM, **Piquette-Miller M**. Expression of ABC Efflux transporters in placenta from women with insulin-managed diabetes. *PLoS One.*; 7(4):e35027. 2012.

Zahedi P, Yoganathan R, **Piquette-Miller M**, Allen C. Recent advances in drug delivery strategies for treatment of ovarian cancer. *Expert Opin Drug Deliv.*; 9(5):567-83. 2012.

Zahedi P, Stewart J, De Souza R, **Piquette-Miller M**, Allen C. An injectable depot system for sustained intraperitoneal chemotherapy of ovarian cancer results in favorable drug distribution at the whole body, peritoneal and intratumoral levels. *J Control Release.*; 158(3):379-85. 2012.

Cressman AM, Petrovic V, **Piquette-Miller M**. Inflammation-mediated changes in drug transporter expression and activity: implications for therapeutic drug response. *Expert Rev Clin Pharmacol.*; 5(1):69-89. 2012.

Pollock BG

Wojtalik JA, Eack SM, **Pollock BG**, Keshavan MS. Prefrontal gray matter morphology mediates the association between serum anticholinergic activity and cognitive functioning in early course schizophrenia. *Psychiatry Res.* 30;204(2-3):61-7, 2012.

Uchida H, Suzuki T, Graff-Guerrero A, Mulsant BH, **Pollock BG**, Arenovich T, Rajji TK, Mamo DC. Therapeutic Window for Striatal Dopamine D2/3 Receptor Occupancy in Older Patients With Schizophrenia: A Pilot PET Study. *Am J Geriatr Psychiatry.* 2012.

Farb NA, Grady CL, Strother S, Tang-Wai DF, Masellis M, Black S, Freedman M, **Pollock BG**, Campbell KL, Hasher L, Chow TW. Abnormal network connectivity in frontotemporal dementia: Evidence for prefrontal isolation. *Cortex.* 2012 Sep 24. doi:pii: S0010-9452(12)00293-6. 10.1016/j.cortex.2012.

Wessels AM, Jin Y, **Pollock BG**, Frank E, Lange AC, Vrijens B, Fagiolini A, Kupfer DJ, Rucci P, Kepple G, Anderton J, Battenfield J, Bies RR. Adherence to escitalopram treatment in depression: a study of electronically compiled dosing histories in the 'Depression: the search for phenotypes' study. *Int Clin Psychopharmacol.*; 27(6):291-7, 2012.

Voineskos AN, Felsky D, Kovacevic N, Tiwari AK, Zai C, Chakravarty MM, Lobaugh NJ, Shenton ME, Rajji TK, Miranda D, **Pollock BG**, Mulsant BH, McIntosh AR, Kennedy JL. Oligodendrocyte Genes, White Matter Tract Integrity, and Cognition in Schizophrenia. *Cereb Cortex.* [Epub ahead of print] 2012.

Sherer EA, Sale ME, **Pollock BG**, Belani CP, Egorin MJ, Ivy PS, Lieberman JA, Manuck SB, Marder SR, Muldoon MF, Scher HI, Solit DB, Bies RR. Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building. *J Pharmacokinet Pharmacodyn.* 39(4):393-414, 2012.

Rajji TK, Chow TW, Voineskos AN, Links KA, Miranda D, Mamo DC, Ismail Z, **Pollock BG**, Mulsant BH. Cholinergic pathways and cognition in patients with schizophrenia: a pilot study. *Schizophr Res.* 139(1-3):46-52, 2012.

Lenze EJ, Dixon D, Nowotny P, Lotrich FE, Doré PM, **Pollock BG**, Hinrichs AL, Butters MA. Escitalopram reduces attentional performance in anxious older adults with high-expression genetic variants at serotonin 2A and 1B receptors. *Int J Neuropsychopharmacol.* 16(2):279-88. Apr 17. PubMed PMID: 22717018.

Chow TW, Fam D, Graff-Guerrero A, Verhoeff NP, Tang-Wai DF, Masellis M, Black SE, Wilson AA, Houle S, **Pollock BG**. Fluorodeoxyglucose positron emission tomography in semantic dementia after 6 months of memantine: an open-label pilot study. *Int J Geriatr Psychiatry*. 28(3):319-25, 2012.

Li CH, **Pollock BG**, Lyketsos CG, Vaidya V, Drye LT, Kirshner M, Sorisio D, Bies RR; for the DIADS-2 Research Group. Population Pharmacokinetic Modeling of Sertraline Treatment in Patients With Alzheimer Disease: The DIADS-2 Study. *J Clin Pharmacol*. 53(2):234-9. Epub 2013 Jan 24

Nebes RD, **Pollock BG**, Perera S, Halligan EM, Saxton JA. The greater sensitivity of elderly APOE $\epsilon 4$ carriers to anticholinergic medications is independent of cerebrovascular disease risk. *Am J Geriatr Pharmacother*. 10(3):185-92, 2012.03.003.

Links KA, Black SE, Graff-Guerrero A, Wilson AA, Houle S, **Pollock BG**, Chow TW. A case of apathy due to frontotemporal dementia responsive to memantine. *Neurocase*. [Epub ahead of print] PubMed PMID: 22515731. 2012.

Uchida H, Mamo DC, **Pollock BG**, Suzuki T, Tsunoda K, Watanabe K, Mimura M, Bies RR. Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study. *Ther Drug Monit*. 34(2):182-7, 2012.

Drye LT, Ismail Z, Porsteinsson AP, Rosenberg PB, Weintraub D, Marano C, Pelton G, Frangakis C, Rabins PV, Munro CA, Meinert CL, Devanand DP, Yesavage J, Mintzer JE, Schneider LS, **Pollock BG**, Lyketsos CG; CitAD Research Group. Citalopram for agitation in Alzheimer's disease: design and methods. *Alzheimers Dement*. 8(2):121-30, 2012.

Sakurai H, Bies RR, Stroup ST, Keefe RS, Rajji TK, Suzuki T, Mamo DC, **Pollock BG**, Watanabe K, Mimura M, Uchida H. Dopamine D2 Receptor Occupancy and Cognition in Schizophrenia: Analysis of the CATIE Data. *Schizophr Bull*. 39(3):564-74, 2012.

Ismail Z, Emeremni CA, Houck PR, Mazumdar S, Rosen J, Rajji TK, **Pollock BG**, Mulsant BH. A Comparison of the E-BEHAVE-AD, NBRs, and NPI in Quantifying Clinical Improvement in the Treatment of Agitation and Psychosis Associated With Dementia. *Am J Geriatr Psychiatry*. [Epub ahead of print] PubMed PMID: 22237247; PubMed Central PMCID: PMC3499650. 2012 Jan 10.

Mizuno Y, Bies RR, Remington G, Mamo DC, Suzuki T, **Pollock BG**, Tsuboi T, Watanabe K, Mimura M, Uchida H. Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: a cross-sectional study. *Prog Neuropsychopharmacol Biol Psychiatry*. 37(1):182-7, 2012.

Gerretsen P, Chakravarty MM, Mamo D, Menon M, **Pollock BG**, Rajji TK, Graff-Guerrero A. Frontotemporoparietal asymmetry and lack of illness awareness in schizophrenia. *Hum Brain Mapp*. 34(5):1035-43, 2012.

Ismail Z, Wessels AM, Uchida H, Ng W, Mamo DC, Rajji TK, **Pollock BG**, Mulsant BH, Bies RR. Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophrenia. *Am J Geriatr Psychiatry*.;20(1):53-60, 2012.

Voineskos AN, Rajji TK, Lobaugh NJ, Miranda D, Shenton ME, Kennedy JL, **Pollock BG**, Mulsant BH. Age-related decline in white matter tract integrity and cognitive performance: a DTI tractography and structural equation modeling study. *Neurobiol Aging*. 33(1):21-34, 2012.

Mizrahi R, Rusjan PM, Kennedy J, **Pollock BG**, Mulsant B, Suridjan I, Deluca V, Bloomfield PM, Wilson AA, Houle S: Translocator protein (18 kDa) polymorphism (rs 6971) explains in-vivo brain binding affinity of the PET radioligand [18F]-FEPPA. *Journal of Cerebral Blood Flow & Metabolism*. 32(6):968-72, 2012.

Riddick DS

Lee C, **Riddick DS**. Aryl hydrocarbon receptor-dependence of dioxin's effects on constitutive mouse hepatic cytochromes P450 and growth hormone signaling components. *Can J Physiol Pharmacol*.; 90(10):1354-63, 2012.

Ross RA

Whyte LS, Ford L, Ridge SA, Cameron GA, Rogers MJ, **Ross RA**. Cannabinoids and bone: endocannabinoids modulate human osteoclast function in vitro. *Br J Pharmacol*.; 165(8):2584-97, 2012.

Díaz-Arteaga A, Vázquez MJ, Vazquez-Martínez R, Pulido MR, Suarez J, Velásquez DA, López M, **Ross RA**, de Fonseca FR, Bermudez-Silva FJ, Malagón MM, Diéguez C, Nogueiras R. The atypical cannabinoid O-1602 stimulates food intake and adiposity in rats. *Diabetes Obes Metab*.; 14(3):234-, 2012.

Moreno-Navarrete JM, Catalán V, Whyte L, Díaz-Arteaga A, Vázquez-Martínez R, Rotellar F, Guzmán R, Gómez-Ambrosi J, Pulido MR, Russell WR, Imbernón M, **Ross RA**, Malagón MM, Dieguez C, Fernández-Real JM, Frühbeck G, Nogueiras R. The L- α -lysophosphatidylinositol/GPR55 system and its potential role in human obesity. *Diabetes*.; 61(2):281-91, 2012.

Anavi-Goffer S, Baillie G, Irving AJ, Gertsch J, Greig IR, Pertwee RG, **Ross RA**. Modulation of L- α -lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. *J Biol Chem*.; 287(1):91-104, 2012.

Nicoll G, Davidson S, Shanley L, Hing B, Lear M, Breen G, Quinn J, McGuffin P, **Ross RA** and MacKenzie A. Alleles of a CBI gene enhancer, associated with obesity, cognitive decline and addiction, show differential responses to MAPkinase activation in hypothalamus and hippocampus. *J Biol Chem*.; 287(16):12828034, 2012.

Salahpour A

Salahpour A, Espinoza S, Masri B, Lam V, Barak LS, Gainetdinov RR. BRET biosensors to study GPCR biology, pharmacology, and signal transduction. *Front Endocrinol (Lausanne)*.; 3:105. doi: 10.3389/fendo, 2012.

Kile BM, Walsh PL, McElligott ZA, Bucher ES, Guillot TS, **Salahpour A**, Caron MG, Wightman RM. Optimizing the Temporal Resolution of Fast-Scan Cyclic Voltammetry. *ACS Chem Neurosci*.; 3(4):285-292, 2012.

Calipari ES, Ferris MJ, Melchior JR, Bermejo K, **Salahpour A**, Roberts DC, Jones SR. Methylphenidate and cocaine self-administration produce distinct dopamine terminal alterations. *Addict Biol*. 2012 Mar 28. doi: 10.1111/j.1369-1600.2012.00456.x. [Epub ahead of print] PubMed PMID: 22458761; 2012.

Managò F, Espinoza S, **Salahpour A**, Sotnikova TD, Caron MG, Premont RT, Gainetdinov RR. The role of GRK6 in animal models of Parkinson's disease and L-DOPA treatment. *Sci Rep*.; 2:301, 2012.

Salahpour A, Caron MG. Food for thought: the physiological relevance of ghrelin and dopamine D2 receptor heterodimerization in the regulation of appetite. *Neuron*.; 73(2):210-1. doi: 10.1016/j.neuron.2012.01.004, 2012.

Schapira M

Senisterra G, Wu H, Allali-Hassani A, Wasney GA, Barsyte-Lovejoy D, Dombrovski L, Dong A, Nguyen KT, Smil D, Bolshan Y, Hajian T, He H, Seitova A, Chau I, Li F, Poda G, Couture JF, Brown PJ, Al-Awar R, **Schapira M**, Arrowsmith CH, Vedadi M. Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5. *Biochem J*.; 449(1):151-9, 2012.

Zheng W, Ibáñez G, Wu H, Blum G, Zeng H, Dong A, Li F, Hajian T, Allali-Hassani A, Amaya MF, Siarheyeva A, Yu W, Brown PJ, **Schapira M**, Vedadi M, Min J, Luo M. Sinefungin derivatives as inhibitors and structure probes of protein lysine methyltransferase SETD2. *J Am Chem Soc*.; 134(43):18004-14, 2012.

Liu L, Zhen XT, Denton E, Marsden BD, **Schapira M**. ChromoHub: a data hub for navigators of chromatin-mediated signalling. *Bioinformatics*.; 28(16):2205-6, 2012.

Siarheyeva A, Senisterra G, Allali-Hassani A, Dong A, Dobrovetsky E, Wasney GA, Chau I, Marcellus R, Hajian T, Liu F, Korboukh I, Smil D, Bolshan Y, Min J, Wu H, Zeng H, Loppnau P, Poda G, Griffin C, Aman A, Brown PJ, Jin J, Al-Awar R, Arrowsmith CH, **Schapira M**, Vedadi M. An allosteric inhibitor of protein arginine methyltransferase 3. *Structure*.; 20(8):1425-35, 2012.

Yu W, Chory EJ, Wernimont AK, Tempel W, Scopton A, Federation A, Marineau JJ, Qi J, Barsyte-Lovejoy D, Yi J, Marcellus R, Iacob RE, Engen JR, Griffin C, Aman A, Wienholds E, Li F, Pineda J, Estiu G, Shatseva T, Hajian T, Al-Awar R, Dick JE, Vedadi M, Brown PJ, Arrowsmith CH,

Bradner JE, **Schapira M**. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. *Nat Commun.* ;3:1288. doi: 10.1038/ncomms2304, 2012.

Arrowsmith CH, Bountra C, Fish PV, Lee K, **Schapira M** - *Nat Rev Drug Discov.* 2012; 11:384-400 - Epigenetic protein families: a new frontier for drug discovery.

Seeman P

Lai TK, **Seeman P**, Liu F. Cell membrane lytic action of metoclopramide and its relation to tardive dyskinesia. *Synapse.*; 66(3):273-6, 2012.

Seeman P. Dopamine agonist radioligand binds to both D2High and D2Low receptors, explaining why alterations in D2High are not detected in human brain scans. *Synapse.* 66(1):88-93, 2012.

Chen S, Lu FF, **Seeman P**, Liu F: Quantitative proteomic analysis of human substantia nigra in Alzheimer's disease, Huntington's disease and Multiple Sclerosis. *Neurochemical Res.* 37 (12): 2805-2813,2012.

Seeman P. Comment on "Effects of a novel mGlu_{2/3} receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid." (Lowe S, Dean R, Ackermann B, Jackson K, Natanegara F, Anderson S, Eckstein J, Yuen E, Ayan-Oshodi M, Ho M, McKinzie D, Perry K, Svensson K, *Psychopharmacology*, 2012). *Psychopharmacology*, 221: 355-356 (2012).

Seeman P, Madras B.K. Imaging of the Human Brain in Health and Disease Neuroscience-Net, neuroscience.com (2012). 19 Chapters. Electronic book.

Seeman P: Comment on "A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia." *J Clin Psychopharmacol* 2011;31:349-355). *J. Clin. Psychopharmacol.* 32(2): 291-292 (2012).

Seeman P, Remington, G: Antipsychotic dosing: Extended, and Transient. *Clin. Schizophrenia & Related Psychoses* July: 86-87, 2012.

Vauquelin G, Bostoen S, Vanderheyden P, **Seeman P**: Clozapine, atypical antipsychotics, and the benefits of fast-off D₂ dopamine receptor antagonism. *Naunyn Schmeideberg's Arch. Pharmacol.* 385(4): 337-372, 2012.

Semple JW

Semple JW, Kim M, Hou J, Lee YJ, Tabuchi A, Kuebler WM, Chai Z-W, Lazarus AH. Intravenous immunoglobulin (IVIg) therapy prevents murine antibody-mediated Transfusion Related Acute Lung Injury (TRALI) at the level of neutrophil activation. *PLoS One* 7(2):e31357, 2012.

Semple JW, Provan D. The immunopathogenesis of immune thrombocytopenia (ITP): T cells still take center-stage. *Curr Opin Hematol* 19(5):357-362, 2012.

Aslam R, Hu Y, Gebremeskel S, Segel GB, Speck ER, Guo L, Kim M, Ni H, Freedman J, **Semple JW**: Thymic Retention of CD4+CD25+FoxP3+ T regulatory cells is associated with their peripheral deficiency and thrombocytopenia in a murine model of immune thrombocytopenia (ITP). *Blood* 120(10):2127-2132, 2012.

Thon JN, Peters CG, Machlus K, Aslam R, Rowley J, Macleod H, Devine MT, Fuchs TA, Wagner DD, Weyrich AS, **Semple JW**, Flaumenhaft R, Italiano Jr. JE. T-granules in human platelets function in TLR9 organization and signaling. *J Cell Biol.* 198(4):561-574, 2012.

Semple JW, Provan D The immunopathogenesis of immune thrombocytopenia: T cells still take center-stage *Curr Opin Haematol.* 19:357–362,2012.

Semple JW. Platelets have a Role as Immune Cells. *Vox Sang.* 7:1-5, 2012.

Semple JW. Bregging rights in ITP. *Blood.* 120(16):3169, 2012.

Shear NH

Shear NH. 'Is it safe?' Safety is a process, not a question. *Br J Dermatol.*; 167(5):968-9, 2012.

Alhusayen RO, Juurlink DN, Mamdani MM, Morrow RL, **Shear NH**, Dormuth CR; Canadian Drug Safety and Effectiveness Research Network. Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study. *J Invest Dermatol.*; 133(4):907-12, 2012.

Baibergenova AT, Weinstock MA, **Shear NH**. Mortality from acquired bullous diseases of skin in Canadian adults 2000-2007. *Int J Dermatol.*; 51(11):1325-8. 2012.

Alavi A, Lowe J, Walsh S, Juurlink D, Mortaz-Hedjri S, **Shear NH**. Corticosteroid-induced hyperglycemia is increased 10-fold in patients with pemphigus. *Int J Dermatol.*; 51(10):1248-52, 2012.

Drucker AM, Baibergenova A, Rosen CF, **Shear NH**. Narrowband UVB as an effective substitute for psoralen plus UVA: lessons from a psoralen shortage. *Photodermatol Photoimmunol Photomed.*; 28(5):267-8, 2012.

Lui H, Gulliver W, Tan J, Hong CH, Hull P, **Shear NH**, Paradiso-Hardy F, Bissonette R. A randomized controlled study of combination therapy with alefacept and narrow band UVB phototherapy (UVB) for moderate to severe psoriasis: efficacy, onset, and duration of response. *J Drugs Dermatol.*; 11(8):929-37, 2012.

Knowles SR, Dewhurst N, **Shear NH**. Anticonvulsant hypersensitivity syndrome: an update. *Expert Opin Drug Saf.*; 11(5):767-78, 2012.

Alhusayen R, **Shear NH**. Pharmacologic interventions for hidradenitis suppurativa: what does the evidence say? *Am J Clin Dermatol.*; 13(5):283-91, 2012.

Matsukura S, Knowles SR, Walsh S, **Shear NH**. Effect of a single-cycle alternative dosing regimen for rituximab for recalcitrant pemphigus: a case series of 9 patients. *Arch Dermatol.* 2012 Jun;148(6):734-9. doi: 10.1001/archdermatol.2011.3320. Erratum in: *Arch Dermatol.* 2012 Aug;148(8):970.

Mittmann N, Knowles SR, Koo M, **Shear NH**, Rachlis A, Rourke SB. Incidence of toxic epidermal necrolysis and Stevens-Johnson Syndrome in an HIV cohort: an observational, retrospective case series study. *Am J Clin Dermatol.*; 13(1):49-54, 2012.

Shram MJ

Li S, Zou S, Coen K, Funk D, **Shram MJ**, Lê AD. Sex differences in yohimbine-induced increases in the reinforcing efficacy of nicotine in adolescent rats. *Addict Biol.* 2012 Jul 11. doi: 10.1111/j.1369-1600.2012.00473.x. [Epub ahead of print]

Shram MJ, Quinn AM, Chen N, Faulknor J, Luong D, Sellers EM, Endrenyi L. Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada: examination of current bioequivalence criteria. *Clin Ther.*; 34(5):1170-81, 2012.

Sun HS

Bae CY, **Sun HS**. Current understanding of TRPM7 pharmacology and drug development for stroke. *Acta Pharmacol Sin.*;34(1):10-6, 2012.

Lu XL, Xu Z, Yao XL, Su FJ, Ye CH, Li J, Lin Y, Wang GL, Zeng JS, Huang RX, Ou JS, **Sun HS**, Wang LP, Pang J, Pei Z. Marine cyclotriptide X-13 promotes angiogenesis in zebrafish and human endothelial cells via PI3K/Akt/eNOS signaling pathway. *Marine Drugs*, 10: 1307-1320, 2012.

Toal C

Toal CB, Meredith PA, Elliott HL. Once daily nifedipine: the formulation dictates the pharmacokinetic characteristics and therapeutic responses. *Int J Clin Pharmacol*, 50(3):202-217, 2012.

Toal CB, Meredith PA, Elliott HL. Long Acting Dihydropyridine Calcium Channel Blockers and Sympathetic Nervous System Activity in Hypertension: A Literature Review of Amlodipine and Nifedipine GITS. *Blood Pressure* 2012; 21(Suppl 1):3-10, 2012.

Tyndale RF

Liu T, David SP, **Tyndale RF**, H Wang, X-Q Yu, W Chen, Q Zhou, W-Q Chen. Relationship between amounts of daily cigarette consumption and abdominal obesity moderated by *CYP2A6* genotypes in Chinese male current smokers, 43(2):253-61, 2012.

Cox LS, Nollen NL, Mayo MS, Choi WS, Faseru B, Benowitz NL, **Tyndale RF**, Okuyemi KS, Ahluwalia JS. Bupropion for smoking cessation in African American light smokers: A randomized controlled trial, 104(4): 290-298, 2012.

Khokhar JY and **Tyndale RF**. Rat brain CYP2B-enzymatic activation of chlorpyrifos to the oxon mediates cholinergic neurotoxicity, 126(2):325-35 2012.

Tang D, Hello B, Mroziwicz M, Fellows L, **Tyndale RF**, Dagher A. Genetic variation in *CYP2A6* predicts neural reactivity to smoking cues as measured using fMRI. 60(4):2136-43 2012.

Binnington MJ, Zhu AZX, Renner CC, Lanier AP, Hatsukami DK, Benowitz NL, **Tyndale RF** *CYP2A6* and *CYP2B6* genetic variation and its association with nicotine metabolism in South Western Alaska Native people. 22(6):429-40, 2012.

Mahar I, Bagot R, Davoli MA, Miksys S, **Tyndale RF**, C-D Walker, M Maheu, S-H Huang, TP Wong, N Mechawar. Developmental hippocampal neuroplasticity in a model of nicotine replacement therapy during pregnancy and breastfeeding. 7(5):e37219, 2012.

Lee W, Ray R, Bergen AW, Swan GE, Thomas P, **Tyndale RF**, Benowitz N L, Lerman C, Conti DV. *DRD1* Associations with Smoking Abstinence Across Slow and Normal Nicotine Metabolizers. 22(7):551-554, 2012.

Kohli U, Pandharipande P, Muszkat M, Sofowora GG, Friedman E, Scheinin M, Ely W, **Tyndale RF**, Choi L, Stein CM, Kurnik D: *CYP2A6* genetic variation and dexmedetomidine disposition. 68(6):937-42, 2012.

Mann A, Miksys SL, Gaedigk A, Kish SJ, Mash DC, and **Tyndale RF** .The neuroprotective enzyme *CYP2D6* increases in the brain with age and is lower in Parkinson's disease patients, 33: 2160–2171, 2012.

Lee W, Bergen AW, Swan GE, Li D, Liu J, Thomas P, **Tyndale RF**, Benowitz NL, Lerman C, Conti DV. Gender Stratified Gene and Gene –Treatment Interactions in Smoking Cessation, 12(6):521-32, 2012

Benowitz NL, Renner CC, Lanier AP, **Tyndale RF**, Hatsukami DK, Lindgren B , Stepanov I, Watson CH, Sosnoff CS, and Jacob P III. Exposure to Nicotine and Carcinogens among South Western Alaskan Native Cigarette Smokers and Smokeless Tobacco Users. 21(6):934-42 2012.

St.Helen G, Novalen M, Heitjan DF, Dempsey D, Jacob P III, Aziziyeh A, Wing VC, George TP, **Tyndale RF**, Benowitz NL. Reproducibility of the Nicotine Metabolite Ratio in Cigarette Smokers. 21(7):1105-14, 2012.

Ferguson CS, Miksys S, Palmour RM, **Tyndale RF**. Differential Effects of Nicotine Treatment and Ethanol Self-administration on CYP2A6, CYP2B6 and Nicotine Pharmacokinetics in African Green Monkeys. 343(3):628-37, 2012.

Zhu AZX, Cox LS, Nollen N, Mayo M, Faseru B, Okuyemi KS, Ahluwalia JS, Benowitz NL, **Tyndale RF**. CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion. 92(6):771-7, 2012.

Miksys S, Uhl K, **Tyndale RF**. Twenty-first century neuroscience: the potential for innovative therapies for brain disorders, 91 (2): 153-157, 2012.

Zhu AZX and **Tyndale RF**. Chapter 17. Nicotine Metabolism and Its Implications, in Metabolism of Drugs and other Xenobiotics, Wiley publishers. Editors, Pavel Anzenbacher and Ulrich M. Zanger, pp 465-492, 2012.

McDonagh EM, Wassenaar C, David SP, **Tyndale RF**, Altman RB, Whirl-Carrillo M, Klein TE. PharmGKB Summary - Very Important Pharmacogene Information for Cytochrome P-450, Family 2, Subfamily A, polypeptide 6 (CYP2A6), 22(9):695-708,2012.

Miksys S and **Tyndale RF**. Cytochrome P450-mediated drug metabolism in the brain Journal of Psychiatry and Neuroscience, 37(6):120-133, 2012.

Utrecht JP

Zhu X, **Utrecht J**. A novel T(H)17-type cell is rapidly increased in the liver in response to acetaminophen-induced liver injury: T(H)17 cells and the innate immune response. J Immunotoxicol. [Epub ahead of print] 2012 Oct 8.

Ng W, **Utrecht J**. Changes in gene expression induced by aromatic amine drugs: Testing the danger hypothesis. J Immunotoxicol.; 10(2):178-91, 2012.

Sharma AM, Li Y, Novalen M, Hayes MA, **Utrecht J**. Bioactivation of nevirapine to a reactive quinone methide: implications for liver injury. Chem Res Toxicol; 25(8):1708-19, 2012.

Ng W, Lobach AR, Zhu X, Chen X, Liu F, Metushi IG, Sharma A, Li J, Cai P, Ip J, Novalen M, Popovic M, Zhang X, Tanino T, Nakagawa T, Li Y, **Utrecht J**. Animal models of idiosyncratic drug reactions. Adv Pharmacol.; 63:81-135, 2012.

Metushi IG, Nakagawa T, **Utrecht J**. Direct oxidation and covalent binding of isoniazid to rodent liver and human hepatic microsomes: humans are more like mice than rats. Chem Res Toxicol.;25(11):2567-76, 2012.

Utrecht, J: Idiosyncratic drug reactions and the role of drug metabolism. In: Radulovic L and Coleman M (Ed) Encyclopedia of Drug Metabolism and Interactions. Wiley, NY, 2012.

Wojcinski Z, **Utrecht, J:** Idiosyncratic drug reactions. In: Radulovic L and Coleman M (Ed) Encyclopedia of Drug Metabolism and Interactions. Wiley, N.Y. 2012.

Verma S

Yanagawa, B, Lovren, F, Pan, Y, Garg, V, Quan, A, Tang, G, Singh, KK, Shukla, PC, Kalra, NP, Peterson, MD, **Verma, S.** MiRNA-141 is a Novel Regulator of BMP-2-Mediated Calcification in Aortic Stenosis. *J Thoracic Cardiovasc Surg.*; 144(1):256-262.e2, 2012.

Gupta M, Singh N, Tsigoulis M, Kajil M, Hirjikaka S, Quan A, Teoh H, **Verma S.** Perceptions of Canadian primary care physicians towards cardiovascular risk assessment and lipid management. *Can J Cardiol.*: 28(1): pp 14-19. 2012.

Gupta M, Teoh H, Kajil M, Tsigoulis M, Quan A, Braga MFB, **Verma S.** The effects of rosiglitazone on inflammatory biomarkers and adipokines in diabetic, hypertensive patients. *Exp Clin Cardiol.*: 17(4): 191-196, 2012.

Lovren F, Pan Y, Quan A, Singh KK, Shukla PC, Gupta N, Steer BM, Ingram AJ, Gupta M, Al-Omran M, Teoh H, Marsden PA and **Verma S.** MicroRNA-145 targeted therapy reduces atherosclerosis. *Circulation.*: 126[suppl 1]: pp S81–S90, 2012.

Singh KK, Shukla PC, Quan A, Desjardins J-F, Lovren F, Pan Y, Garg V, Gosal S, Garg A, Szmitko PE, Schneider MD, Parker TG, Stanford WL, Leong-Poi H, Teoh H, Al-Omran, M, **Verma S.** BRCA2 deficiency exaggerates doxorubicin induced cardiac failure. *J Biol Chem.*: 287: pp 6604-14, 2012.

Warsh JJ

Roedding AS, Gao AF, Au-Yeung W, Scarcelli T, Li PP, **Warsh JJ.** Effect of oxidative stress on TRPM2 and TRPC3 channels in B lymphoblast cells in bipolar disorder. *Bipolar Disord.*; 14(2):151-61, 2012.

Wells PG

Siu MT, Wiley MJ, **Wells PG.** Methanol teratogenicity in mutant mice with deficient catalase activity and transgenic mice expressing human catalase. *Reprod Toxicol.*; 36:33-9, 2012.

Ondovcik SL, Tamblyn L, McPherson JP, **Wells PG.** Oxoguanine glycosylase 1 (OGG1) protects cells from DNA double-strand break damage following methylmercury (MeHg) exposure. *Toxicol Sci.*; 128(1):272-83, 2012.

Abramov JP, Tran A, Shapiro AM, **Wells PG.** Protective role of endogenous catalase in baseline and phenytoin-enhanced neurodevelopmental and behavioral deficits initiated in utero and in aged mice. *Reprod Toxicol.*; 33(3):361-73, 2012.

Wong ACH

Lipina TV, Haque FN, McGirr A, Berger T, Mak TW, Boutros PC, Roder JC, **Wong AH**: Prophylactic valproic acid treatment prevents schizophrenia-related behaviour in *Disc1*-L100P mutant mice, *PLoS one*; 7(12) e51562, 2012.

Teo C, Zai C, Borlido C, Tomasetti C, Strauss J, Shinkai T, Le Foll B, **Wong A**, Kennedy JL, De Luca V. Analysis of treatment-resistant schizophrenia and 384 markers from candidate genes. *Pharmacogenet Genomics*; 22(11):807-11, 2012.

Khare T, Pai S, Koncevicius K, Pal M, Kriukiene E, Liutkeviciute Z, Irimia M, Jia P, Ptak C, Xia M, Tice R, Morera S, Nazarians A, Belsham D, **Wong AHC**, Blencowe BJ, Wang SC, Kapranov P, Kustra R, Labrie V, Klimasauskas A, Petronis P. 5-hmC is abundant in synaptic genes and shows differences at the exon-intron boundary. *Nature Structural and Molecular Biology*; 19(10):1037-43, 2012.

Wang M, **Wong AH**, Liu F: Interactions between NMDA and dopamine receptors: a potential therapeutic target. *Brain Research*; 1476:154-63, 2012.

Zawadzki J, Woodward TS, Sokolowski HM, Boon HS, **Wong AH**, Menon M: Cognitive factors associated with subclinical delusional ideation in the general population, *Psychiatry Research*; 197: 345-349, 2012.

Haque FN, Lipina TV, Roder JC, **Wong AH**. Social defeat interacts with *Disc1* mutations in the mouse to affect behaviour. *Behavioral Brain Research*; 233(2): 337-344. 2012.

Asefa D, Haque FN, **Wong AH**. Case Report: Anxiety and fear in a patient with meningioma compressing the left amygdala. *Neurocase*; 18(2):91-4, 2012.

Labrie V, **Wong AH**, Roder JC: Contributions of the D-serine pathway to schizophrenia, *Neuropharmacology*; 62(3):1484-503 (ISI 2010 impact factor: 4.677), 2012.

De Luca V, Zai C, De Souza R, Polsinelli G, Teo C, Shinkai T, **Wong A**, Le Foll B, Kennedy JL: Admixture analysis of age at onset in schizophrenia: Genetic association study of 45 candidate loci. *Schizophrenia Research*; 134(2-3):288-90 (ISI 2010 impact factor 4.374), 2012.

Wong AH and Liu F: Uncoupling the dopamine D1-D2 receptor complex: a novel target for antidepressant treatment, *Clinical Pharmacology and Therapeutics*; 91(2):298-302, 2012.

Favalli G, Li J, Belmonte-de-Abreu P, **Wong AH**, Daskalakis ZJ. The role of BDNF in the pathophysiology and treatment of schizophrenia. *Journal of Psychiatric Research*; 46(1):1-11, 2012.

Young T

Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, O'Donovan C, Macqueen G, McIntyre RS, Sharma V, Ravindran A, **Young LT**, Milev R, Bond DJ, Frey BN, Goldstein BI,

Lafer B, Birmaher B, Ha K, Nolen WA, Berk M. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. *Bipolar Disord.*;15(1):1-44, 2012.

Scola G, Kim HK, **Young LT**, Andreazza AC. A fresh look at complex I in microarray data: clues to understanding disease-specific mitochondrial alterations in bipolar disorder. *Biol Psychiatry.*;15;73(2):e4-5. , 2012.

Gigante AD, Bond DJ, Lafer B, Lam RW, **Young LT**, Yatham LN. Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis. *Bipolar Disord.*; 14(5):478-87, 2012.

Hajek T, Cullis J, Novak T, Kopecek M, Blagdon R, Propper L, Stopkova P, Duffy A, Hoschl C, Uher R, Paus T, **Young LT**, Alda M. Brain structural signature of familial predisposition for bipolar disorder: replicable evidence for involvement of the right inferior frontal gyrus. *Biol Psychiatry*; 73(2):144-52, 2012.

Parikh SV, Zaretsky A, Beaulieu S, Yatham LN, **Young LT**, Patelis-Siotis I, Macqueen GM, Levitt A, Arenovich T, Cervantes P, Velyvis V, Kennedy SH, Streiner DL. A randomized controlled trial of psychoeducation or cognitive-behavioral therapy in bipolar disorder: a Canadian Network for Mood and Anxiety treatments (CANMAT) study [CME]. *J Clin Psychiatry.*; 73(6):803-10, 2012.

Hajek T, Cullis J, Novak T, Kopecek M, Höschl C, Blagdon R, O'Donovan C, Bauer M, **Young LT**, Macqueen G, Alda M. Hippocampal volumes in bipolar disorders: opposing effects of illness burden and lithium treatment. *Bipolar Disord.*; 14(3):261-70, 2012.

Bieling PJ, Hawley LL, Bloch RT, Corcoran KM, Levitan RD, **Young LT**, Macqueen GM, Segal ZV. Treatment-specific changes in decentering following mindfulness-based cognitive therapy versus antidepressant medication or placebo for prevention of depressive relapse. *J Consult Clin Psychol.*; 80(3):365-72, 2012.

Hajek T, Bauer M, Pfennig A, Cullis J, Ploch J, O'Donovan C, Bohner G, Klingebiel R, **Young LT**, Macqueen GM, Alda M. Large positive effect of lithium on prefrontal cortex N-acetylaspartate in patients with bipolar disorder: 2-centre study. *J Psychiatry Neurosci.*; 37(3):185-92, 2012.

Kandratavicius L, Hallak JE, **Young LT**, Assirati JA, Carlotti CG Jr, Leite JP. Differential aberrant sprouting in temporal lobe epilepsy with psychiatric co-morbidities. *Psychiatry Res.*; 195(3):144-50, 2012.

Blumberger DM, Mulsant BH, Fitzgerald PB, Rajji TK, Ravindran AV, **Young LT**, Levinson AJ, Daskalakis ZJ. A randomized double-blind sham-controlled comparison of unilateral and bilateral repetitive transcranial magnetic stimulation for treatment-resistant major depression. *World J Biol Psychiatry.*; (6):423-35, 2012.

Zack M

Boileau I, Payer D, Chugani B, Lobo D, Behzadi A, Rusjan PM, Houle S, Wilson AA, Warsh J, Kish SJ, **Zack M**. The D(2/3) dopamine receptor in pathological gambling: a positron emission tomography study with [(11) C]-(+)-propyl-hexahydro-naphtho-oxazin and [(11) C]raclopride. *Addiction*. 2012 Nov 20. doi: 10.1111/add.12066. [Epub ahead of print].

Boileau I, Payer D, Houle S, Behzadi A, Rusjan PM, Tong J, Wilkins D, Selby P, George TP, **Zack M**, Furukawa Y, McCluskey T, Wilson AA, Kish SJ. Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. *J Neurosci* 25; 32(4):1353-9, 2012.

Aramakis VB, Khamba BK, MacLeod CM, Poulos CX, **Zack M**. Alcohol selectively impairs negative self-relevant associations in young drinkers. *J Psychopharmacol.*; 26(2):221-31, 2012.

Zawertailo L

Lobo DS, **Zawertailo L**, Selby P, Kennedy JL. The role of ANKK1 and TTC12 genes on drinking behaviour in tobacco dependent subjects. *World J Biol Psychiatry*; 13(3):232-8, 2012.

Zawertailo L, Dragonetti, R, Bondy, S, Victor C, Selby P. Reach and effectiveness of mailed nicotine replacement therapy for smokers: six-month outcomes in a naturalistic, exploratory study *Tobacco Control* 2012 Apr 26 [Epub]

Yilmaz Z, Kaplan AS, **Zawertailo LA**. Bulimia nervosa and alcohol use disorder: evidence for shared etiology and neurobiology. *Curr Psychiatry Rev.*; 8(1):69-81, 2012.

Ph.D. Theses (2012)

Ahmed, Shaimaa (2012). Molecular Mechanisms at Aryl Hydrocarbon Receptor Transactivation and Crosstalk with Estrogen Receptor Alpha. Supervisor: Dr. J. Matthews.

Chuang, Andrew (2012). Hypertonicity Regulation of Cytochrome P450 CYP3A. Supervisor: Dr. S. Ito.

Creed, Meaghan (2012). Deep Brain Stimulation of the Subthalamic and Entopeduncular Nuclei in an Animal Model of Tardive Dyskinesia. Supervisor: Dr. J. Nobrega.

Khokhar, Jkibran (2012). An Investigation of CYP2B in Rat Brain: Regulation and Role in Drug and Toxin Response. Supervisor: Dr. R.F. Tyndale.

Liuni, Andrew (2012). Assessment of Endothelial Function in Humans and the Endothelial-Protective Effects of the 4-hydroxy-3-methylglutaryl coenzyme A Reductase. Inhibitors. Supervisor: Dr. J.D. Parker

Luca, Mary Clare (2012). Assessment of Endothelial Function and Approaches to Prevent Ischemia and Reperfusion-induced Endothelial Dysfunction in Humans. Supervisor: Dr. J.D. Parker.

Sarras, Haya (2012). A Role for Bclaf1 in mRNA Processing and Skeletal Muscle Differentiation. Supervisor(s): Dr. J.P. McPherson & Dr. D.S. Riddick.

Swardfager, Walter (2012). Cardiopulmonary Fitness, Depressive Symptoms and Cognitive Performance in Patients With Coronary Artery Disease: Phenomenology and Biomarkers. Supervisor: Dr. K.L. Lanctôt.

Trepanier, Catherine (2012) Genetic-epigenetic Interactions: Sequence-Dependent and Independent DNA Methylation. Supervisor(s): Dr. J. MacDonald & Dr. M. Salter.

M.Sc. Theses (2012)

Carey, Nathalie (2012). The Long-Term Neurocognitive Development of Children Exposed to Above Manufacturer Recommended Doses of Diclectin in Utero. Supervisor: Dr. G. Koren.

Chugani, Bindiya (2012). Parallels Between Gambling and Amphetamine Reinforcement in Pathological Gamblers and Healthy Controls and the Role of Sensitization. Supervisor: Dr. M. Zack.

Cressman, Alexander (2012). P. berghei Experimental Malaria Infection Alters Drug Transporter and Drug Metabolizing Enzyme Expression in Pregnancy. Supervisor: Dr. M. Piquette-Miller.

Dedina, Liana (2012). Riboflavin Transporters and Breast Cancer Resistance Protein: Cimetidine-Riboflavin Interactions in the Mammary Gland. Supervisor: Dr. S. Ito.

Doucet, Jean Sébastien (2012) Animal Models of Prophylaxis and Prevention of Schizophrenia: Prenatal Seasonal Influenza Vaccine and Postnatal Valproate. Supervisor: Dr. A. Wong.

Li, Buren (2012). Structural Studies of the Klebsiella Pneumoniae Pantothenate Kinase in Complex with Pantothenamide Substate Analogues. Supervisor: Dr. H-W. Park & Dr. J.P. McPherson.

Matlow, Jeremy (2012). The Transfer of Ethyl Glucuronide in the Dually Perfused Ex Vivo Placental Perfusion Model: Implications for Alcohol Screening During Pregnancy. Supervisor: Dr. G. Koren.

Natekar, Aniket (2012). Cocaethylene as a Biomarker in Human Hair of Concomitant Alcohol and Cocaine Use in a High-Risk Population. Supervisor: Dr G. Koren.

Park, Mina (2012). Search for DNA Methylation Biomarkers in the Circulating DNA of Prostate and Colorectal Cancer. Supervisor: Dr. A. Petronis.

Tatone, Daniel (2012). Comparative Effects of a D2 and Mixed D1-D2 Dopamine Receptor Antagonist on Amphetamine Reinforcement in Pathological Gamblers and Healthy Controls. Supervisor: Dr. M. Zack.

Rajakulendran, Nishani (2012). Neuronal UV-Initiated Apoptosis is Prevented by 5-Bromo-2'-Deoxyuridine (BrdU) or a Deficiency in Cockayne Syndrome B or Xeroderma Pigmentosum A. Supervisor: Dr. R. Laposa.

Tong, Steven (2012) Role of Oxidative Stress on Neural TRPC3, TRPC5 and TRPC6 Expression and/or Function and Relevance to Bipolar Disorder. Supervisor: Dr. J.J. Warsh.

Utgikar, Rucha (2012). Down-Regulation of Cytochrome P450 2C8 by 3-Methylcholanthrene in Human Hepatocellular Carcinoma Cell Lines. Supervisor: Dr. D.S. Riddick.

(Zarek) Davidovits, Judith (2012). A Re-assessment of the Risk: Benefit Analysis of Statin Therapy During Pregnancy: Do Benefits of Treatment Outweigh Putative Reproductive Risks. Supervisor: Dr. G. Koren.

Zhou, Kaidi (2012). Inhibition of Brain CYP2D Lowers Codeine-Induced Analgesia in Rats. Supervisor: Dr.R.F. Tyndale.